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Abstract
The objective of this research project was to develop a drug delivery system for
recombinant human erythropoietin (rHu-EPO), a glycoprotein hormone used in the treatment of
renal anaemia and chemotherapy induced anaemia, using the biopolymer chitosan as the base
component. Two types of chitosan nanoparticles were produced through ionotropic gelation
using flush mixing with either tripolyphosphate (TPP) or carrageenan polymer. Chitosan-TPP
and chitosan-carrageenan nanoparticles were generated under a variety of conditions to evaluate
the effects of chitosan concentration, chitosan to anion mass ratio and solution pH on the
nanoparticle characteristics of particle diameter, surface charge and particle size distribution. A
statistical method of experimentation design, known as response surface modeling, was applied
to allow for accurate manipulation of nanoparticle characteristics and to create nanoparticles with
optimized characteristics.
The encapsulation and controlled release of rHu-EPO from chitosan nanoparticles was
evaluated with chitosan-TPP nanoparticles demonstrating an encapsulation efficiency of
43.45±0.84% and ~68% drug release within two weeks, while chitosan-carrageenan
nanoparticles had an encapsulation efficiency of 47.97±4.10% and ~50% drug release within two
weeks. Both types of chitosan nanoparticles exhibited improved encapsulation and release of
rHu-EPO compared to previous results. Also, the molecular weight of the chitosan used and the
surface charge of the nanoparticles were shown to have an effect on the encapsulation and
release of rHu-EPO.

Keywords: Chitosan, Drug delivery, Erythropoietin, Ionotropic gelation, Nanoparticles,
Response surface modeling

iii

Acknowledgements
I would like to thank my research supervisor, Professor Argyrios Margaritis, for the support and
guidance he provided throughout the rigors of my thesis research and for his enduring positive
attitude.
Much gratitude is given to Dr. Denis O’Carroll for allowing me to use his, Zeta Plus, dynamic
light scattering device and to Tim Stephens for his training on this piece of equipment.
I would also like to thank Dr. Stanley Dunn for providing access to his fluorometer and Lee-Ann
Briere for her much needed instruction and guidance.
The rHu-EPO provided for this research by Dr. Anargyros Xenocostas was greatly appreciated.
The suggestions, encouragement and sometimes well needed distractions provided by the other
members of Dr. Margaritis’s research group, S. Armirnia, L. Cheng, R. Gomez, F. Hellmers and
I. Reiniati, were deeply appreciated and will not be forgotten.
Lastly, I would like to thank my family and close friends for their continued support, motivation
and advice throughout my university career.
This work was supported by the Natural Sciences and Engineering Research Council (NSERC)
of Canada through Discovery Grant No. 4388 awarded to Dr. A. Margaritis.

iv

Table of Contents
CERTIFICATE OF EXAMINATION ........................................................................................... ii
Abstract .......................................................................................................................................... iii
Acknowledgements ........................................................................................................................ iv
List of Figures .............................................................................................................................. viii
List of Tables ................................................................................................................................ xii
Nomenclature ............................................................................................................................... xiv
Abbreviations ............................................................................................................................... xvi
Chapter 1 ......................................................................................................................................... 1
1

Introduction ............................................................................................................................. 1

Chapter 2 ......................................................................................................................................... 4
2

Nanotechnology in Drug Delivery .......................................................................................... 4
2.1 Why Apply Nanotechnology to Drug Delivery .................................................................... 5
2.3 Nano-Drug Delivery Systems ............................................................................................... 8
2.3.1 Polymeric Nanoparticles................................................................................................. 9
2.3.2 Polymeric Micelles ....................................................................................................... 10
2.3.3 Dendrimers ................................................................................................................... 11
2.3.4 Liposomes ..................................................................................................................... 11
2.3.5 Metallic Nanostructures ................................................................................................ 12
2.3.6 Nanocrystals ................................................................................................................. 13
2.3.7 Buckyballs and Carbon Nanotubes............................................................................... 14
2.4 Challenges of Applying Nanotechnology ........................................................................... 15
2.5 Conclusion........................................................................................................................... 16

v

Chapter 3 ....................................................................................................................................... 17
3

Chitosan-based Nano-Drug Delivery Systems ...................................................................... 17
3.1 Methods of Producing Chitosan Nanoparticles ................................................................... 18
3.1.1 Coacervation/Precipitation ........................................................................................... 19
3.1.2 Emulsion-droplet Coalescence ..................................................................................... 20
3.1.3 Reverse Micelles........................................................................................................... 21
3.1.4 Ionotropic Gelation ....................................................................................................... 22
3.2 Drug Delivery Applications of Chitosan Nanoparticles ..................................................... 23
3.3 Conclusion........................................................................................................................... 24

Chapter 4 ....................................................................................................................................... 26
4

Materials and Methods .......................................................................................................... 26
4.1 Materials .............................................................................................................................. 26
4.1.1 Chemicals and Equipment ............................................................................................ 26
4.1.2 Description of Important Chemicals............................................................................. 27
4.2 Methods ............................................................................................................................... 30
4.2.1 Preparation of Chitosan Nanoparticles ......................................................................... 30
4.2.2 Chitosan Nanoparticle Physiochemical Characterization ............................................. 31
4.2.3 Particle Morphology – Transmission Electron Microscopy ......................................... 38
4.2.4 Statistical Analysis ....................................................................................................... 39
4.2.5 Encapsulation of rHu-Erythropoietin ........................................................................... 41
4.2.6 Controlled Release of rHu-Erythropoietin ................................................................... 42
4.2.7 Fluorometer Measurement ............................................................................................ 42

Chapter 5 ....................................................................................................................................... 44
5

Chitosan Nanoparticle Characterization – Screening Process ............................................... 44

vi

5.1 Screening Characterization of Chitosan-TPP Nanoparticles .............................................. 45
5.2 Chitosan-TPP Nanoparticle Morphology ............................................................................ 51
5.3 Screening Characterization of Chitosan-Carrageenan Nanoparticles ................................. 53
5.4 Chitosan-Carrageenan Nanoparticle Morphology .............................................................. 58
Chapter 6 ....................................................................................................................................... 60
6

Chitosan Nanoparticle Response Surface Modelling ............................................................ 60
6.1 Chitosan-TPP Nanoparticle RSM ....................................................................................... 61
6.2 Chitosan-Carrageenan Nanoparticle RSM .......................................................................... 65

Chapter 7 ....................................................................................................................................... 69
7

Encapsulation and Controlled Release of rHu-EPO .............................................................. 69
7.2 Chitosan-TPP – Encapsulation and Controlled Release ..................................................... 70
7.3 Chitosan-Carrageenan – Encapsulation and Controlled Release ........................................ 74

Chapter 8 ....................................................................................................................................... 78
8

Conclusions and Recommendations ...................................................................................... 78
8.1 Conclusions ......................................................................................................................... 78
8.2 Recommendations................................................................................................................80

References ..................................................................................................................................... 82
Appendices .................................................................................................................................... 90
Appendix A – Screening Process .............................................................................................. 90
Appendix B – Chitosan Nanoparticle Response Surface Modeling ....................................... 114
Appendix C – Encapsulation and Controlled Release of rHu-EPO ........................................ 118

vii

List of Figures
Figure 1-1: Primary Structure of Human Erythropoietin. ............................................................... 3
Figure 2-1: Typical drug concentration profile within blood. ........................................................ 6
Figure 2-2: Examples of nano- drug delivery systems. .................................................................. 8
Figure 3-1: Structure of Chitosan a) Monomer b) Cross-linked chitosan. ................................... 18
Figure 4-1: Structure of sodium tripolyphosphate. ....................................................................... 29
Figure 4-2: Structure of κ-, ι- and λ- carrageenan......................................................................... 29
Figure 4-3: Schematic diagram of chitosan nanoparticle production ........................................... 31
Figure 4-4: Typical correlogram from a sample containing large particles and a sample
containing small particles.. ........................................................................................................... 32
Figure 4-6: Typical lognormal distribution for chitosan-TPP nanoparticles.. .............................. 34
Figure 4-5: Schematic diagram of a DLS instrument. .................................................................. 34
Figure 4-7: Schematic diagram of the ZetaPlus electrode. ........................................................... 36
Figure 4-8: Schematic diagram of ZetaPlus zetasizer................................................................... 37
Figure 4-9: Typical zeta potential measurement for chitosan-TPP nanoparticles.. ...................... 38
Figure 4-10: Schematic diagram of a TEM instrument. ............................................................... 39
Figure 4-11: Orientation of points for trial conditions when considering a three factor design a)
Central Composite Design b) Face Centered Cubic Design (CCD with α = 1) c) Box-Behnken
Design.. ......................................................................................................................................... 40
Figure 4-12: Schematic diagram of the Fluorolog3 instrument. ................................................... 42
Figure 5-1: Effect of chitosan concentration and chitosan to TPP mass ratio on the mean particle
diameter of chitosan-TPP nanoparticles. ...................................................................................... 46
Figure 5-2: Effect of chitosan concentration and chitosan to TPP mass ratio on the zeta potential
of chitosan-TPP nanoparticles.. .................................................................................................... 47

viii

Figure 5-3: Effect of chitosan concentration and chitosan to TPP mass ratio on the polydispersity
of chitosan-TPP nanoparticles. ..................................................................................................... 47
Figure 5-4: Effect of pH level on A) the mean particle diameter, B) zeta potential and C)
polydispersity of chitosan-TPP nanoparticles.. ............................................................................. 49
Figure 5-5: Effect of chitosan MW on A) the mean particle diameter, B) zeta potential and C)
polydispersity of chitosan-TPP nanoparticles.. ............................................................................. 50
Figure 5-6: TEM image of a chitosan-TPP nanoparticle. ............................................................. 52
Figure 5-7: TEM image of a group chitosan-TPP nanoparticles. ................................................. 52
Figure 5-8: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the mean
particle diameter of chitosan-carrageenan nanoparticles. ............................................................. 53
Figure 5-9: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the
polydispersity of chitosan-carrageenan nanoparticles.. ................................................................ 54
Figure 5-10: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the zeta
potential of chitosan-carrageenan nanoparticles. .......................................................................... 55
Figure 5-11: Effect of pH level on A) the mean particle diameter and B) zeta potential of
chitosan-carrageenan nanoparticles.. ............................................................................................ 56
Figure 5-12: Effect of chitosan MW on A) the mean particle diameter, B) zeta potential and C)
polydispersity of chitosan-carrageenan nanoparticles. ................................................................. 57
Figure 5-13: TEM image of a chitosan-carrageenan nanoparticle................................................ 58
Figure 5-14: TEM image of a group chitosan-carrageenan nanoparticles. ................................... 59
Figure 6-1: Response surface 3D models and contour plots displaying the relationship between
chitosan concentration and chitosan to TPP mass ratio with the mean particle diameter of
chitosan-TPP nanoparticles for the pH values of 5.0, 5.5 and 6.0. ............................................... 63
Figure 6-2: Response surface 3D models and contour plots displaying the relationship between
chitosan concentration and chitosan to TPP mass ratio with the zeta potential of chitosan-TPP
nanoparticles for the pH values of 5.0, 5.5 and 6.0. ..................................................................... 64

ix

Figure 6-3: Response surface 3D models and contour plots displaying the relationship between
chitosan concentration and chitosan to TPP mass ratio with the polydispersity of chitosan-TPP
nanoparticles for the pH values of 5.0, 5.5 and 6.0. ..................................................................... 64
Figure 6-4: Response surface 3D models and contour plots displaying the relationship between
chitosan concentration and chitosan to carrageenan mass ratio with mean particle diameter of
chitosan-carrageenan nanoparticles for the pH values of 4.5, 5.0 and 5.5. .................................. 67
Figure 6-5: A) Response surface 3D model and B) contour plot of the relationship between
chitosan concentration and chitosan to carrageenan mass ratio with the polydispersity of
chitosan-carrageenan nanoparticles.. ............................................................................................ 67
Figure 6-6: Response surface 3D models and contour plots displaying the relationship between
chitosan concentration and chitosan to carrageenan mass ratio with the zeta potential of chitosancarrageenan nanoparticles for the pH values 4.5, 5.0 and 5.5 ...................................................... 68
Figure 7-1: Comparison of rHu-EPO percent release over time for chitosan-TPP nanoparticles
produced using low, medium and high MW chitosan. ................................................................. 72
Figure 7-2: Comparison of rHu-EPO percent release over time for chitosan-TPP nanoparticles
with surface charges of ~30mV, ~35mV and ~40mV.. ................................................................ 73
Figure 7-3: Comparison of rHu-EPO percent release over time for chitosan-carrageenan
nanoparticles produced using low, medium and high MW chitosan.............................................76
Figure 7-4: Comparison of rHu-EPO percent release over time for chitosan-carrageenan
nanoparticles with surface charges ~40mV, ~45mV and ~50mV.................................................77
Figure A-1: Effect of chitosan concentration and chitosan to TPP mass ratio on the mean particle
diameter of chitosan-TPP nanoparticles (Scatter plot).. ............................................................... 97
Figure A-2: Effect of chitosan concentration and chitosan to TPP mass ratio on the zeta potential
of chitosan-TPP nanoparticles (Scatter plot). ............................................................................... 98
Figure A-3: Effect of chitosan concentration and chitosan to TPP mass ratio on the polydispersity
of chitosan-TPP nanoparticles (Scatter plot).. .............................................................................. 98

x

Figure A-4: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the mean
particle diameter of chitosan-carrageenan nanoparticles (Scatter plot).. .................................... 109
Figure A-5: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the zeta
potential of chitosan-carrageenan nanoparticles (Scatter plot).. ................................................. 110
Figure A-6: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the
polydispersity of chitosan-carrageenan nanoparticles (Scatter plot). ......................................... 110
Figure C-1: Example of rHu-EPO fluorometer intensity readings used in creation of calibration
curve. ........................................................................................................................................... 118
Figure C-2: Example of rHu-EPO calibration curve applied for conversion of intensity to
concentration. .............................................................................................................................. 119
Figure C-3: Comparison of the cumulative mass of rHu-EPO released over time for chitosanTPP nanoparticles produced using low, medium and high MW chitosan.. ................................ 120
Figure C-4: Comparison of the cumulative mass of rHu-EPO released over time for chitosanTPP nanoparticles with surface charges of ~30mV, ~35mV and ~40mV. ................................. 122
Figure C-5:Comparison of the cumulative mass of rHu-EPO released over time for chitosancarrageenan nanoparticles produced using low, medium and high MW chitosan.. .................... 123
Figure C-6: Comparison of the cumulative mass of rHu-EPO released over time for chitosancarrageenan nanoparticles with surface charges of ~40mV, ~45mV and ~50mV. .................... 125

xi

List of Tables
Table 4-1: List of chemicals used during this research study. ..................................................... 26
Table 4-2: List of equipment used during this research study. ..................................................... 27
Table 4-3: Main chemical components' net molecular charge as a function of pH. ..................... 28
Table 4-4: Nanoparticle production conditions for encapsulation and controlled release study .. 41
Table 6-1: Chitosan-TPP nanoparticle RSM fit characteristics. ................................................... 62
Table 6-2: Chitosan-carrageenan nanoparticle RSM fit characteristics. ...................................... 65
Table 7-1: rHu-EPO encapsulation results within chitosan-TPP. ................................................. 70
Table 7-2: Comparison of particle diameter and zeta potential between blank and EPO loaded
chitosan-TPP nanoparticles. .......................................................................................................... 71
Table 7-3: rHu-EPO encapsulation results within chitosan-carrageenan. .................................... 74
Table 7-4: Comparison of particle diameter and zeta potential between blank and EPO loaded
chitosan-carrageenan nanoparticles. ............................................................................................. 75
Table A-1: Chitosan-TPP nanoparticle diameter characterization. .............................................. 90
Table A-2: Chitosan-TPP nanoparticle zeta potential characterization.. ...................................... 92
Table A-3: Chitosan-TPP nanoparticle polydispersity characterization.. ..................................... 94
Table A-4: Chitosan-TPP nanoparticle solution pH study data. ................................................... 96
Table A-5: Chitosan-TPP nanoparticle MW study, particle diameter characterization.. ............. 99
Table A-6: Chitosan-TPP nanoparticle MW study, zeta potential characterization.. ................. 100
Table A-7: Chitosan-TPP nanoparticle MW study, polydispersity characterization.. ................ 101
Table A-8: Chitosan-carrageenan nanoparticle diameter characterization. ................................ 102
Table A-9: Chitosan-carrageenan nanoparticle zeta potential characterization.. ....................... 104
Table A-10: Chitosan-carrageenan nanoparticle polydispersity characterization.. .................... 106
Table A-11: Chitosan-carrageenan nanoparticle solution pH study data. .................................. 108
xii

Table A-12: Chitosan-carrageenan nanoparticle MW study, particle diameter characterization 111
Table A-13: Chitosan-carrageenan nanoparticle MW study, zeta potential characterization.. .. 112
Table A-14: Chitosan-carrageenan nanoparticle MW study, polydispersity characterization. .. 113
Table B-1: Chitosan-TPP nanoparticle RSM data.......................................................................114
Table B-2: Chitosan-carrageenan nanoparticle RSM data...........................................................116
Table C-1: Chitosan MW study - rHu-EPO release from chitosan-TPP nanoparticles, cumulative
mass release.................................................................................................................................119
Table C-2: Chitosan MW study - rHu-EPO release from chitosan-TPP nanoparticles, percent
release..........................................................................................................................................120
Table C-3: Zeta Potential study - rHu-EPO release from chitosan-TPP nanoparticle, cumulative
mass release.................................................................................................................................121
Table C-4: Zeta Potential study - rHu-EPO release from chitosan-TPP nanoparticles, percent
release..........................................................................................................................................121
Table C-5: Chitosan MW study - rHu-EPO release from chitosan-carrageenan nanoparticles,
cumulative mass release...............................................................................................................122
Table C-6: Chitosan MW study - rHu-EPO release from chitosan-carrageenan nanoparticles,
percent release..............................................................................................................................123
Table C-7: Zeta Potential study - rHu-EPO release from chitosan-carrageenan nanoparticles,
cumulative mass release...............................................................................................................124
Table C-8: Zeta Potential study - rHu-EPO release from chitosan-carrageenan nanoparticles,
percent release..............................................................................................................................125

xiii

Nomenclature
a

=

Particle radius (nm)

A

=

Instrument optical constant

B

=

Correlation function intercept

cmin

=

Minimum drug concentration in blood (IU• L-1)

d

=

Hydrodynamic diameter (cm)

D

=

Translational diffusion coefficient (cm2 •s-1)

ei

=

Residuals

E

=

Electric field strength (kg•m•s-3•A-1)

G

=

Correlation function

n

=

Refractive index

PRESS

=

Predicted residual sum of squares

q

=

Scattering vector (rad)

R2

=

Coefficient of determination

R2Adj

=

Adjusted coefficient of determination

R2Pred

=

Predicted coefficient of determination

SSCorTotal

=

Sum of squares relative to the mean

SSModel

=

Sum of the squares relative to zero

T

=

Absolute temperature (°K)

xiv

vs

=

Average drift velocity (cm•s-1)

X

=

Chitosan concentration (mg•mL-1)

Y

=

Chitosan-TPP or Chitosan-carrageenan mass ratio

Z

=

Solution pH

α

=

Response surface modeling axial point variance

Γ

=

Fluctuation relaxation (rad•s-1)

ε

=

Relative permittivity of the liquid

ζ

=

Zeta potential (V)

η

=

Liquid viscosity (cP or Pa•s)

θ

=

Scattering angle (°)

κ

=

Boltzmann’s constant (1.38054 x 10-16ergs•degrees-1)

κ-1

=

Double layer thickness (nm)

λ

=

Laser wavelength (nm)

μ

=

Proportional to the variance in translational diffusion coefficient distribution

μe

=

Electrophoretic mobility (cm2•V-1•s-1)

τ

=

Time delay (s)

ωD

=

Doppler shift frequency (Hz)

xv

Abbreviations
BBD

-

Box-Behnken design

CCD

-

Central composite design

CS

-

Chitosan

CG

-

Carrageenan

DLS

-

Dynamic light scattering

DNA

-

Deoxyribonucleic acid

EPO

-

Erythropoietin

FCC

-

Face center cubic

2FI

-

Two-factor interaction terms

HIV

-

Human immunodeficiency virus

LD

-

Lethal dose

LDE

-

Laser Doppler electrophoresis

LUV

-

large unilamellar vesicles

MI

-

Acute myocardial infarction

MLV

-

Multilamellar vesicles

MRI

-

Magnetic resonance imaging

MW

-

Molecular weight

OFAT

-

One-factor-at-a-time

xvi

PBS

-

Phosphate buffered solution

PEG

-

Polyethylene glycol

PLA

-

polylactic acid

PLGA

-

poly (lactide-co-glycolide)

PMT

-

Photomultiplier tube

Qdots

-

Quantum dots

RES

-

Reticulo-endothelial system

rHu-EPO

-

Recombinant human erythropoietin

RSM

-

Response surface modeling

R&D

-

Research and development

STP

-

Standard temperature and pressure

SUV

-

Small unilamellar vesicles

TEM

-

Transmission electron microscopy

xvii

Chapter 1
1 Introduction
The existence of erythropoietin (EPO) was first theorized in the early 1900s, but the
hormonal regulator of red blood cell production was not identified until 1977 through the effort
of Eugene Goldwasser, who after 17 years of work was able to isolate EPO through the
purification of urine from aplastic anaemia patients [1, 2]. EPO is a glycoprotein hormone,
produced in the renal interstitial cells of the kidney, which regulates the quantity of red blood
cells within the body. Haemopoiesis is the biological process of blood cell formation, which is
controlled by erythropoietin along with several other glycoproteins and paracrine peptides, such
as thrombopoietin and interleukins [3]. The molecular weight of EPO is approximately 3036kDa and consists of 165 amino acid residues [4-6]. EPO’s structure contains 3 N-linked acidic
oligosaccharides positioned at asparagines 24-, 38- and 83-, and 1 O-linked oligosaccharide at
serine 126 (Fig. 1). These carbohydrates are comprised of fucose, mannose, Nacetylfucoseamine, galactose and N-acetylneuraminic acid, and make up 40% of EPO’s mass, as
well as control EPO’s half-life in the body [3, 5-7].
Recombinant human erythropoietin (rHu-EPO) is applied in the treatment of renal
anaemia and chemotherapy induced anaemia [8, 9]. Commercial production of rHu-EPO is done
using Chinese hamster ovary cell lines and is a multi-billion dollars industry [1, 10]. The
polypeptide sequence of rHu-EPO has been determined to be identical to that of human
erythropoietin displaying full in vitro and in vivo biological activity [10, 11]. The possibility of
rHu-EPO having tissue protective properties in organ systems, such as the cardiovascular and
central nervous systems, after ischemic injury and during oxidative stress via mechanisms that
include inhibition of apoptosis, decreased inflammation and promotion of angiogenesis has been
the focus of many recent studies [12-17].
Patient discomfort and treatment expenses are high due to rHu-EPO’s short half-life (8.5
hours) after IV injection, which means the therapeutic agent must be administered frequently [9,
18]. The use of rHu-EPO at high doses and or over prolonged periods of time increase the
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patient’s risk of elevated blood pressure, thrombosis, chronic heart dilation, ventricular oedema,
acute cardiac failure and other issues [14]. Biopolymer nanoparticles could be utilized as an
encapsulation and controlled release vehicle in hopes of decreasing the enzymatic breakdown of
the hormone and thus lower the clearance rate of rHu-EPO, while at the site of injury providing a
controlled release that maintains the necessary therapeutic concentration. This method would
also lower the systemic exposure of the patient to rHu-EPO, which is advantageous for the
reasons described.
The overall goal of this research project was to explore methods of encapsulating rHuEPO within biopolymer nanoparticles. The biopolymer chitosan (CS) was selected as the
component of choice due its many beneficial properties and characteristics that make it an ideal
drug excipient. Another advantage of chitosan is that due to its positive charge it is naturally
attracted to EPO, which has a negative charge above its isoelectric point of 4.3, and chitosan has
an affinity for the sialic acid found in rHu-EPO [19]. Chitosan has been used as a component of
both microparticles and nanoparticles, which have been trialed as a vehicle for drug delivery in a
variety of applications [20]. A literature review led to the selection of ionotropic gelation as the
most desirable method of nanoparticle production due its mild process conditions. It was decided
to produce two different chitosan nanoparticles, both produced through ionotropic gelation, using
the gelling agents tripolyphosphate (TPP) and carrageenan (CG), and to compare their
effectiveness as drug delivery vehicles. The nanoparticle production process was to be
thoroughly explored with the objective of producing nanoparticles with the most desirable
characteristics through the application of response surface modeling (RSM). The key
nanoparticle characteristics were identified to be nanoparticle size, surface charge and size
distribution. These optimized nanoparticles were then tested for their ability to encapsulate and
control release rHu-EPO.

2

Figure 1-1: Primary Structure of Human Erythropoietin.

3

Chapter 2
2 Nanotechnology in Drug Delivery
Nanotechnology is a multidisciplinary field, which has shown explosive growth over the
last few decades, and involves the engineering and manufacturing of materials at the atomic and
molecular scale. Nanotechnology has been defined, by the National Nanotechnology Initiative,
as structures of approximately 1-100nm in size in at least one dimension, but it has become
common to refer to structures that are up to several hundred nanometers in size and that are
generated through either top-down or bottom-up engineering of individual components as
nanomaterials [21]. One of the major areas of expansion has been related to applications in the
field of drug delivery. Drug delivery is the technique or process of administering a
pharmaceutical compound or therapeutic agent to humans or animals in order to treat a condition
or disease. There are hundreds of pharmaceuticals developed every year costing tens of millions
of dollars to develop and although a substantial amount of these pharmaceutical compounds are
approved by governing bodies for clinical applications, their method of administration has
remained fundamentally unchanged. These methods consist mainly of drug molecules in their
native form being administered through various routes, including oral, topical or intravenous
injections. At the same time, the major pharmaceutical companies are saying that the rate of
generation of new pharmaceuticals is decreasing and due to patent legislation (Hatch-Waxman
Act) the generic pharmaceutical companies are successfully challenging their patents. Both of
which could have sever negative effects on pharmaceutical revenues and R&D as a whole [22].
With these issues and the emergence of research in the field of biotechnology a significant
interest in developing novel drug delivery systems that improve both the pharmacological and
therapeutic properties of the original pharmaceutical compounds has formed, which has led to
the exploration of nanotechnological improvements. The application of nanotechnology in the
field of drug delivery has arisen due to a variety of advantages, such as lower drug
concentrations, slower drug release, and site targeting. Nano-drug delivery systems also come in
an assortment of structures, which include nanoparticles, both polymeric and solid lipid,
polymeric micelles, dendrimers, liposomes, nanocrystals, metallic nanostructures, buckyballs
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and carbon nanotubes [23, 24], that either integrate the therapeutic agent into the matrix or attach
it to the particle surface with each having their own advantages and disadvantages.

2.1 Why Apply Nanotechnology to Drug Delivery
The first advantage provided by nanoparticles is the obvious, their small size. The small
dimensions of nano-drug delivery systems allow the particles to penetrate tissue barriers that
large particles are unable to permeate [23]. The size of the drug delivery system is also important
from an immune perspective because the particles must be sufficiently diminutive to avoid
detection and clearance by the macrophage. Studies, in vitro and in vivo, have shown that both
the size and shape of nanostructures determine their ability to cross the threshold of cells and
tissues [25, 26], with one study finding that colloidal nanoparticles with sizes near 50nm were
the most efficient at cellular uptake [27].
The general goal and benefit that drug delivery systems try to achieve, nano-drug
delivery systems are no different, is to provide a sustained and controlled release of the
pharmaceutical agent. Figure 2-1 shows the concentration profile of a drug in the body; every
time the drug concentration reaches cmin more drugs must be administered. Nano-drug delivery
systems hope to provide a more stable concentration of therapeutic agent that avoids maximums
and minimums and provides treatment over a longer period of time, in order to reduce the
number of times medication needs to be administered. The rate of drug release from nano-drug
delivery systems is controlled by the mass transfer characteristics of the drug carrier, which are
affected by factors like porosity and particle degradation, and can be manipulated to alter the
drug concentration profile within the patient. Reducing the number of times a drug must be
administered can significantly increase patient comfort and quality of life, since many drugs
require intrusive methods of application, such as repeated injection and intravenous
administration. Another potential benefit of developing drug delivery systems, that can avoid
macrophage detection and provide a controlled release, is that many drugs, such as
chemotherapy drugs, have a variety of adverse affects on patients that reducing patient exposure
can limit [23].
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Figure 2-1: Typical drug concentration profile within blood.

The next benefit is the potential for improved delivery of drugs that have poor water
solubility. Nano-drug delivery systems provide the ability to encapsulate or chemically bind
pharmaceuticals that have poor solubility or are insoluble in water, which allows for their
transportation through water environments. Besides improving the delivery of previously
approved therapeutic agents, the encapsulation of water insoluble drugs may allow for
researchers to revisit previously discarded drugs, reopening a significant portion of the
pharmaceutical tool box, and providing more and better options for treatments [21].
One of the major reasons for the growing interest in nano-drug delivery systems is the
potential to generate targeted delivery and triggered release of drugs to specific cells and tissues.
Drug targeting delivery systems should be capable of controlling the fate of a drug entering the
patient. Current delivery technologies are a long way away from the so called “magic bullet” that
was proposed by Paul Ehrlich at the beginning of the 1900s, where the drug is precisely targeted
to the exact site of action. The nano-drug delivery systems that have been clinically approved
thus far are relatively simple in structure and lack targeting and/or triggered drug release
mechanisms. Interest in the concept of drug targeting has increased greatly over the decade with
the arrival of new technologies and better understanding of the processes behind both cellular
and sub-cellular drug delivery [28]. Targeted delivery is divided into active and passive
targeting, where active targeting refers to the conjugation of the drug or the carrier system to a
tissue or cell-specific ligand and passive targeting refers to the coupling of the drug to a
macromolecule that passively reaches the target organ [29]. Being able to target sites and release
drugs under certain environmental conditions would prevent the release of therapeutics that may
6

have harmful side-effects in regions of the body that do not require treatment and would ensure
that therapeutics reach their intended target.
There is also the potential to co-deliver two or more therapeutic agents, which would
eliminate the need to create multiple drug delivery systems and simplify the treatment process by
ensuring that all the necessary drugs for therapeutic treatment of a condition are working as a
cohesive unit. Along the same stream of thought it is possible that imaging modalities also be
included in the nanostructure to allow for simultaneous therapeutic relief and imaging. An
example is research, by Mulder et al., where semiconductor nanocrystals, known as quantum
dots, were conjugated to paramagnetic lipids allowing for both magnetic resonance imaging
(MRI) and fluorescence [30]. This means that conjugating drug molecules to these nanoparticle
surfaces can provide additional functionalities. The ultimate goal would be to use one nano-drug
delivery system to diagnose a patient with a disease, maybe cancer, using enhanced MRI
imaging and then use fluorescence emissions from quantum dots within the nanostructure to help
physicians complete real-time tumour removal using optical guidance, while encapsulated drug
molecules provide post-surgical adjuvant therapy [23]. These multifunctional nano-drug delivery
systems, providing a universal platform for detection, imaging and delivering, will simplify
treatment, reduce treatment time and potentially cut costs.
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2.3 Nano-Drug Delivery Systems
As previously mentioned, there are a variety of nano-drug delivery systems and some of
the systems that will be reviewed are shown in Figure 2-2.

A)

B)

C)

D)

Magnetic
Core

Polymer Shell

F)

E)

Therapeutic Agent

Targeting Molecule

Hydrophilic Functional Group

Figure 2-2: Examples of nano- drug delivery systems: A) Polymeric nanoparticles/micelles, B) Liposome, C) Dendrimers,
D) Magnetic nanoparticles, E) Carbon nanotubes and F) Buckyballs.
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2.3.1 Polymeric Nanoparticles
The application of biodegradable polymers in the formation of nanoparticles is an area of
drug delivery that has garnered much attention over the last few decades. Nanoparticles are
known as solid colloidal particles made up of a large polymeric structure and are in the range of
10nm to 1000nm in size [29]. Nano-polymer drug delivery systems can come in the form of
nanoparticles, nanospheres or nanocapsules depending upon their method of preparation and
either dissolve, entrap, adsorb, attach or encapsulate therapeutic agents in their structure [29]. A
nanosphere physically holds and uniformly disperses drug within its matrix system, while a
nanocapsule confines the drug to the space within the polymer membrane of its vesicular system.
The structure and method of drug capture define the structural properties and the release
characteristics of the drug.
Polymeric nanoparticles are of particular interest for development of efficient drug
delivery systems for release within the cytoplasmic environment. Firstly, the tiny dimensions of
nanoparticles allow them to access smaller capillaries and to be taken up by cells, which improve
drug accumulation at the target site [31]. The biodegradable materials used in formation of the
nanoparticles permit sustained release of the therapeutic agent over a longer period of time, days
or weeks, at the target site. These theories were observed in action, when dexamethasone-loaded
nanoparticles were able to provide greater and sustained antiproliferation in vascular smooth
muscle cells than drug within solution [32]. Polymeric nanoparticles have also been applied to
the delivery of antigens for vaccination, since there are problems with rapid vaccine degradation
and limited uptake by immune cells. Studies have demonstrated that polymeric micro and
nanoparticles systems reduce vaccine degradation and improve cellular uptake [33, 34]. Another
area of application for nanoparticles is in the delivery of therapeutic agents across the bloodbrain barrier, which has long been a challenge and held up treatment of diseases, like human
immunodeficiency virus (HIV). Poly-(butylcyanoacrylate) nanoparticles coated with polysorbate
80 have been demonstrated as an efficient method of transporting hexapeptide dalargin and other
agents into the brain [35]. Further, enhancement of polymeric nanoparticles through the
application of both active and passive forms of targeted drug delivery has been investigated [36].
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2.3.2 Polymeric Micelles
Amphiphilic block copolymers that are capable of self-associating to form micelles in
aqueous solution are a type of polymeric nano-drug delivery system that has gained interest in
the past decades and has been extensively studied as a drug carrier. When compared to
conventional surfactant micelles, polymeric micelles have a few advantages over their
counterparts in that they provide enhanced thermodynamic stability in physiological solution,
which is indicated by their low critical micellar concentration. This generates polymeric
micelles’ stability and prevents their rapid dissociation in vivo [37]. Micelles have a reasonably
narrow size distribution, with sizes less than ~100nm, and are distinguished by their distinctive
core-shell structure, where the hydrophobic elements are kept out of contact with the exterior
aqueous environment. Micellar systems, like liposomes to be discussed later, are useful for the
systemic delivery of water-insoluble drugs. The micellar structure allows for the (hydrophobic or
lipophilic) drug to be stored in the hydrophobic core of micelles and the outer hydrophilic layer
to form a stable dispersion in the aqueous media, which can then be intravenously administered.
The size and surface properties dictate the distribution of the drug loaded polymeric micelles
within the body. Polymeric micelle drug delivery systems are able to avoid renal exclusion and
the reticulo-endothelial system (RES) and exhibit enhanced endothelial cell permeability around
solid tumour sites due to their small dimensions [38].
It has been demonstrated that polymeric micelles that have been administered
intravenously have an extended circulation time due to their smaller size and hydrophilic shell,
which reduce the micelle uptake by the RES. Also, polymeric micelle drug carriers may provide
a greater accumulation of drug than free drug in tumours and have demonstrated a reduced
circulation to non-targeted areas.
Polymeric micelles may also be improved by the addition of targeting mechanisms
through conjugation of targeting ligands, including antibodies, to the micelle surface. Antitumour antibody-conjugated polymeric micelles, known as immunomicelles, used to encapsulate
the water-insoluble drug Taxol within the hydrophobic core of the micelles were successfully
recognized and bound to a variety of cancer cells in vitro [19]. This study also confirmed that
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immunomicelles in contrast to non-targeted micelles had the ability to deliver higher
concentrations of drugs to mice tumours.
2.3.3 Dendrimers
Dendrimers are macromolecular compounds that consist of a series of branches around an
inner core. More specifically, dendrimer molecules are monodisperse symmetric
macromolecules constructed about a minute molecule or linear polymer core through connectors
and branching units. The nanometer size range of dendrimers, like all nano-drug delivery
carriers, are one attractive aspect that makes them interesting as a drug delivery system, but they
also provide ease of preparation and functionalization, as well as possess the ability to present
multiple copies of surface groups for biological reorganization processes [29]. For the most part,
interaction between the dendrimer macromolecules and the molecular environment is controlled
by their terminal groups; thus, through modifications to their termini, the interior of a dendrimer
can be made hydrophobic, while the exterior surface is hydrophilic, or the opposite. Dendrimers
can be manufactured through either divergent synthesis, where construction starts from the
central core and works outwards to the periphery, or convergent synthesis, where construction
begins in a top-down approach with formation of the exterior residues. Due to the type of
monomers used in dendrimer production each layer of branching units doubles or triples the
number of peripheral functional groups. Dendrimers’ globular shape and internal cavities allow
for encapsulation of drugs within the macromolecule interior, which combined with their ability
to attach drugs to surface groups gives them two modes drug capture. An advantage of
dendrimers in their water-soluble form is their ability to bind and solubilize small molecules,
deliver drugs to specific sites in the body and act as means of timed release for biologically
active agents.
2.3.4 Liposomes
Liposomes have been employed as an adaptable tool in the fields of biochemistry and
medicine, since they were initially proposed for use as a drug delivery carrier in 1969 [39]. The
achievements of liposomes as a nano-drug delivery system have to date been much greater than
any other nano system. Liposomes are spherical in shape, small in dimension and can be created
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using natural non-toxic phospholipids and cholesterols. Liposomes are considered to be
promising drug delivery carriers because of their hydrophobic and hydrophilic bilayer, as well as
their biocompatibility. The properties of liposomes depend significantly on the lipid
composition, size, surface charge and the production method. Liposomes are categorized into
three groups dependent on their number of bilayers and size. Small unilamellar vesicles (SUV)
contain a single lipid layer and have a diameter between 25–50 nm, while large unilamellar
vesicles (LUV) also only have a single lipid layer, but are greater than 50nm in diameter [40].
The third category, multilamellar vesicles (MLV), is constructed with several lipid layers with a
layer of aqueous solution between each lipid layer. The materials used to create the lipid layer(s)
control the stability of the bilayer, as well as the bilayer’s charge. Generally, saturated
phospholipids form more stable and fairly impermeable bilayers, while unsaturated
phospholipids from natural sources produce less stable and more permeable bilayers. The
liposome surface charge is completely dependent on the charge of the lipid used. Liposomes
have the ability to decrease degradation of the encapsulated drug within the patient and to reduce
systemic toxicity [41]. Liposome surface modification using polyethylene glycol (PEG) has been
shown to improve their circulation time in the bloodstream and has earned them the nickname
“stealth liposomes” [42]. The surface of liposomes can also be modified with antibodies or
ligands to allow for targeted drug delivery.
2.3.5 Metallic Nanostructures
Metallic nanostructures have a history in application as biosensors and contrast probes for
imaging, diagnostics and therapeutic purposes; colloidal gold nanoparticles are an example of
such structures that have been explored for biosensing and imaging applications. Metallic
nanostructures display changes in quantum mechanical properties (surface plasma resonance and
surface enhanced Raman scattering) when the nanoparticle size is altered [43]. Another reason
for the interest in metallic nanostructures for drug delivery applications is the relative ease with
which biomolecules may be attached onto their surfaces using different affinity interactions, as
well as their ability to conjugate antibody-based drugs for improved drug delivery.
The physical properties of gold nanoparticles also allow for control over the amplitude
and rate of drug release. An example is a study on the addition of gold nanoshells to the structure
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of hydrogel networks. The gold nanoshells have the ability to generate heat upon optical
excitation of various energies. This allowed drug release to be triggered by increasing the
temperature above the lower critical solution temperature, which caused the hydrogel network to
collapse. Applying gold nanoshells with different thickness allows for their dielectric properties
to be altered; thus, yielding a method of controlling the drug release rate [44].
Another interesting sub-group of metallic nanostructures are magnetic nanoparticles. For
starters, magnetic nanoparticles (ferric oxide nanoparticles) have been included in the structure
of polymeric spheres and used for encapsulation and targeted release of therapeutic agents [45].
Magnetic nanoparticles can be used in a method similar to a homing device, where the external
magnetic field is manipulated to direct drugs to the targeted site, after which the polymer
elements degrade slowly releasing the therapeutic agent [46].
2.3.6 Nanocrystals
The current fluorescent markers used in research and clinical diagnostic applications have
a number of intrinsic shortcomings, which include the requirement of colour-matched lasers, the
fluorescence bleaching, and the lack of discriminatory capacity of multiple dyes; however,
fluorescent nanocrystals have the potential to eliminate these issues. Nanocrystals, also known as
quantum dots (Qdots), are crystalline clumps consisting of a few hundred atoms, coated with an
insulating outer shell of a different material [29]. For the most part Qdots are constructed of
atoms from group II–VI or III–V of the periodic table and by definition are particles with
physical dimensions smaller than the excitation Bohr radius [29, 47]. These tiny particles emit an
extremely bright fluorescence, when hit by a photon of visible light, due to their quantumphysics all of the photon’s energy is reflected to the crystal core. It is possible to detect a cell
carrying a single Qdot [29]. Qdots are able to absorb a wide range of light wavelengths;
however, they emit a nearly monochromatic light whose wavelength is dependent on the crystal
size [47]. By varying size Qdots can emit light at every wavelength from infrared to ultraviolet,
with larger Qdots emitting red light and smaller Qdots emitting blue light. Qdots are very stable
and less toxic than organic dyes due to their inert surface coating and can be attached to
biological materials (cells, proteins and nucleic acids). Qdots can be incorporated into other
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nanomaterials to make a hybrid nanoparticle that has the potential to be used for diagnostic,
imaging and therapeutic applications all at once.
2.3.7 Buckyballs and Carbon Nanotubes
The discovery of fullerenes, which were a new allotropic form of elemental carbon, other
than diamond and graphite, in the 1980s acted as a catalyst in spurring the development of
nanotechnology. One of the major obstacles for the application of fullerenes as drug carriers is
their hydrophobic nature; however, research has shown that by functionalizing the surface of
buckyballs with hydrophilic groups, such as carboxylic (-COOH) and primary amines (NH3), it
is possible to make these fullerenes water miscible [48]. These functionalized buckyballs are
capable of penetrating cell membranes and other barriers, like the blood-brain-barrier, which
allows for drug delivery to sites beyond the realm of traditional drug delivery systems.
Buckyballs have been shown to be swiftly distributed within a variety tissues and organs upon
intravenous injection [49]. Also, chemotherapy drugs have demonstrated an affinity to
functionalized buckyballs, with conjugated paclitaxel exhibiting a half-life in bovine plasma four
times that of free paclitaxel [50].
Carbon nanotubes are cylindrical fullerenes that are hydrophobic in nature; thus, like
buckyballs they require functionalization of their surfaces with biocompatible groups to be
water-miscible. A few strategies for rendering them water-miscible have arisen, including strong
acid-based oxidation through reductive chemistry, which yields surfaces with carboxylic groups.
Another method applies diazonium chemistry to attach functional groups to their side walls using
covalent linkages. Functionalized carbon nanotubes can be associated with a variety of
molecules, including peptides, nucleic acids, proteins and therapeutic agents allowing for
delivery [23]. Carbon nanotubes are able to efficiently enter cells, which has lead to their
involvement in gene therapy.
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2.4 Challenges of Applying Nanotechnology
Despite all of the advantages and potential of applying nanotechnology to drug delivery
there are still quite a few road blocks that need to be overcome. Firstly, there are concerns about
the biosafety of some of the nano-vehicles, which means products like fullerenes, Qdots and
metallic nanoparticles application in medicine are many years away due to this problem. The
biosafety problems arise from inadequate biocompatibility, poor solubility and lack of
biodegradability properties of the previously mentioned particles, which could lead to serious
problems if applied to long term patient therapy [23, 24]. The applications of these particles in
their current form may be acceptable for short term (1-2 weeks) or single dose scenarios without
serious side-effects; however, this seriously limits their usefulness [24]. It has been reported
that fullerenes induce cellular cytotoxicity in vitro. Qdots are composed of heavy metal ions
(cadmium, selenium, etc.), which means when oxidation or enzymatic degradation of the
nanocrystals occur these toxic heavy metal ions may be released [23]. Another reason for
concern is that due to the nanoparticle size and physical characteristics they are able to take on
catalytic properties when in vivo, which generates and enhances their toxic effects. Also, the
ability to be engulfed, which is due again to physical characteristics, presents more problems as
the likelihood of direct damage to cell internals is increased [24].
The very promising, magnetic targeted nanoparticles have made great progress during in
vitro and small animal testing; however, there are critical challenges when applied to larger
animals that need a solution. One of the major issues is that when using the present technology of
rare earth magnets it is not possible to reach nanoparticle targets that are further than a few
centimeters from the magnet, due to the considerable increase in the magnetic field gradient with
an increase in distance, which produces more rapid field strength decay further from the core
[23]. Other forms of targeted delivery face issues with the host identifying the particles as
foreign due to their surface properties, which results in their detection by the RES. These
particles also have problems with adsorption of plasma proteins onto their surfaces that mark
them for phagocyte removal (known as opsonisation) [23].
Another major hurdle when considering commercialization is large scale production of
nanoparticles, which has provided considerable difficulty in up-scaling laboratory methods to
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commercial standards. There are some companies capable of producing fullerenes on an
industrial scale, Carbon Nanotechnologies and Sumitomo; however, they have had difficulty
producing surface modified products [51]. These problems are even more challenging for
processes applying a bottom – up approach.

2.5 Conclusions
The nanotechnology revolution has begun and shows enormous promise in the field of
drug delivery. Nanotechnology has the potential to improve patient quality of life through
decreased administrations due to longer drug release profiles and decreased side-effects due to
reduced concentrations of toxic medications and targeted delivery. The ultimate drug delivery
system that provides a universal platform for diagnosis, imaging and therapeutic treatment is
another lofty goal that may be achieved through the application of nanotechnology. Although
nanotechnology has great potential and has shown positive results, there are still quite a few
obstacles affecting their successful application including possible toxicity issues and challenges
with large-scale production. Based on the literature review of nanotechnology in drug delivery it
was decided to proceed with the intention of developing a nanoparticle drug delivery system for
the encapsulation and controlled release of rHu-EPO. Liposomes and polymeric nanoparticles
were selected as the most suitable due to their biocompatibility and non-toxic nature.
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Chapter 3
3 Chitosan-based Nano-Drug Delivery Systems
Chitosan is a polysaccharide that has been used in a variety of industries, including waste
water treatment, cosmetics, food and nutrition, photography, textiles, and the medical and
pharmaceutical industries. Within the medical and pharmaceutical industries, chitosan has been
applied to ophthalmology, artificial skin generation, chitosan-based wound dressings and drug
delivery [52]. Chitosan is comprised of repeating β-(1-4)-linked D-glucosamine and N-acetyl-Dglucosamine units (Fig. 3-1) generated by the alkaline N-deacetylation of chitin [53, 54].
Chitosan is available in molecular weights ranging from 3000 to 20000 Da and percent
deacetylated from 66 to 95% [55]. Chitin is the major structural component of crustaceans’
exoskeletons and as such is second only to cellulose as the most abundant polysaccharide,
making chitosan a readily available and cheap biopolymer [53]. Chitin itself is structurally
similar to cellulose, but is chemically inert limiting it applications. The main difference between
chitosan and cellulose is that chitosan is composed of 2-amino-2-deoxy-h-d-glucan combined
with glycosidic linkages and the primary amine groups are the source of the properties that
spawn chitosan’s usefulness in pharmaceutical applications [55]. Chitosan is a weak base
polysaccharide and a cation in acidic solutions, due to its free amine groups which become
protonated, making it water soluble.
Interest in the application of natural polymers as components of drug delivery systems
has greatly increased over the past decade. Natural polymers have distinct advantages over their
synthetic counterparts; commonly natural polymers are non-toxic, biodegradable and allow for
cell-specific targeting. Chitosan is biocompatible with living organisms and tissues as it does not
cause any allergic or rejection reactions and is biodegradable since it breaks down gradually
leaving harmless amino sugars that the body absorbs, as its products [55]. The mucoadhesive
[56, 57, 58] and low toxicity [58, 59, 60] properties of chitosan have been well documented and
have fuelled the continual investigation of chitosan drug delivery systems. Chitosan’s
mucoadhesive properties increase the residual time at the site of absorption; thus, increasing
efficiency of drug delivery. Unlike many hydrophobic and amphiphilic polymers, such as poly
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(lactide-co-glycolide) (PLGA) and poly(lactic) acid (PLA)–poly(ethylene)glycol (PEG),
chitosan can avoid the use of hazardous organic solvents during the nanoparticle production
process because it is soluble in aqueous acidic solution [61]. Chitosan’s free amine groups and
cationic nature allow for ionic crosslinking with multivalent anions for the production of
nanoparticles. Chitosan’s positive charge also allows for particles to act as permeation enhancer
across epithelial cell membranes. It is because of these many benefits and advantageous
properties that chitosan is of particular interest in the field of nano-drug delivery. Chitosan as a
base component has been explored for use in buccal, intestinal, nasal, periodontal, wound
healing and many other drug delivery systems [61], which have taken the form of beads [62],
microcapsules [54], microspheres [54], nanoparticles [63, 64] and tablets [65].

Figure 3-1: Structure of Chitosan a) Monomer b) Cross-linked chitosan.

3.1 Methods of Producing Chitosan Nanoparticles
There are a variety of methods that can be used to produce chitosan nanoparticles,
including coacervation/precipitation, emulsion-droplet coalescence, ionotropic gelation and
reverse micellar methods. When selecting a method the requirements for particle size, thermal,
structural and chemical stability, residual toxicity, polydipsersity, and the release kinetics of the
final product must be considered. Method selection also depends on the intended therapeutic
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agent for delivery, as well as the nanoparticle patient application procedure. The four previously
mentioned production methods will be described, as they are currently the most used procedures.
3.1.1 Coacervation/Precipitation
The coacervation/precipitation method is based on the physical and chemical properties
of chitosan, which make it insoluble in alkaline pH medium. This insolubility in alkaline medium
means that chitosan precipitates/coacervates out of solution when mixed with an alkaline
solution. One method of applying these principles to generate chitosan nanoparticles is to blow
chitosan solution into an alkali solution using a compressed air nozzle. Commonly sodium
hydroxide, NaOH-methanol or ethanediamine alkali solutions are used. The particles are
separated and purified either through filtration, centrifugation or both and are then put through
successive washing with hot and cold water [55]. The particle size is controlled through altering
the compressed air pressure and/or the spray-nozzle diameter. The release mechanics can be
altered through the addition of a crosslinking agent, such as glutaraldehyde, to harden the
particles. This method is most commonly used for microparticle production, but can be applied
for nanoparticle production.
The method that is most frequently used for chitosan nanoparticle production is known as
complex coacervation. This method involves the rapid mixing of chitosan solution with drug
loaded alkali solution. In particular chitosan- deoxyribonucleic acid (DNA) nanoparticles for
transfection applications have been produced using this technique. One such study mixed equal
volumes of chitosan solution and preheated (50-55°C) DNA and sodium sulphate solution, at pH
of 5.5, through vortexing for 15-30 seconds [66]. This study investigated the key factors of
DNA, chitosan and sodium sulphate concentration, temperature, pH, amino to phosphate ratio
and chitosan and DNA molecular weight. Nanoparticles with narrow size distributions and
particle size between 100–250 nm were produced when the amino to phosphate group ratio was
between 3 and 8 and chitosan concentration was 100µg/mL. This study also showed that the
particle surface charge (zeta potential) was between +12 to +18 mV for pH levels lower than 6.0,
but became more neutral with an increase in pH above this level. Another study of chitosanpDNA particles produced particles with particle size between 450-820nm, surface charge of +9
to +18mV, encapsulation efficiency between 90.4 and 98%, depending on chitosan’s degree of
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deacetylation, and complete release within 24hr in phosphate buffered saline solution (PBS) [67].
Both studies showed chitosan–DNA nanoparticles could partially protect the encapsulated
plasmid DNA from nuclease degradation.
3.1.2 Emulsion-droplet Coalescence
The emulsion-droplet coalescence method employs both precipitation and emulsion
cross-linking principles. Unlike the emulsion cross-linking methods applied to produced chitosan
microparticles, which cross-links stable droplets, in this method precipitation is induced by
allowing the merging (coalescence) of chitosan droplets with NaOH droplets. This method was
first utilized by Tokumitsu et al [68]. The first step is to produce a stable emulsion containing
aqueous chitosan and therapeutic agent solution, which is generated in liquid paraffin oil. The
same process is used to produce another stable emulsion containing chitosan aqueous solution in
NaOH. Then the emulsions are mixed using high-speed stirring, which causes random collisions
and coalescence of droplets from each emulsion; thus, precipitating chitosan droplets and
producing nanoparticles.
Tokumitsu et al encapsulated gadopentetic acid using this method for gadolinium
neutroncapture therapy [68]. They found that particle size depends upon the degree of chitosan
deacetylation, which as it decreased the particle size increased, while drug encapsulation
efficiency decreased. However, increasing the gadopentetic acid concentration in the chitosan
solution did not increase the particle size and did increase the encapsulation efficiency. Their
investigation produced nanoparticles with a mean particle size of 452 nm and 45% gadopentetic
acid loading using 100% deacetylated chitosan. It should be noted that the nanoparticles were
obtained within the emulsion-droplet and that the size of the nanoparticles was not connected to
the droplet size. This is a prime example of selecting the production process based on all factors
including drug properties. The gadopentetic acid is a bivalent anionic compound which
electrostatically interacts with the amine groups of chitosan; however, this interaction would not
happen if a particle production method that utilizes a cross-linking agent that blocks the free
amine groups of chitosan was used. Therefore, by using the coalescence method the
encapsulation efficiency is optimized.
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3.1.3 Reverse Micelles
Reverse micelles are mixtures of water, oil and surfactant that are thermodynamically
stable and have a dynamic behaviour. When viewing up-close at the microscopic scale, the
structure of reverse micelles consists of aqueous and oil volumes separated by surfactant films,
as the observer zooms out to a more macroscopic scale reverse micelles appear homogeneous
and isotropic. The advantage of reverse micellar formation is that ultrafine polymeric
nanoparticles with narrow size distributions are produced, while applying traditional emulsion
polymerization methods larger nanoparticles (>200nm) are formed with broad size distributions
[55]. The reverse micelle aqueous core acts as a nanoreactor in preparation of ultrafine
nanoparticles. The minute dimensions and narrow size distribution of nanoparticles produced
through the reverse micellar method are due the small size of the reverse micellar droplets
themselves, which are usually between 1 and 10 nm in dimension, and their high degree of
monodispersity [55]. Reverse micelles experience continuous coalescence and re-separation on a
timescale that fluctuates from milliseconds to microseconds due to their constant Brownian
motion. Thus, through a rapid dynamic equilibrium the system is able to preserve its size,
polydispersity and thermodynamic stability.
When performing the reverse micelle method, surfactant is first dissolved in an organic
solvent in order to create the reverse micelles and then the chitosan and drug aqueous solution is
added under constant vortexing to avoid any turbidity. The system can be manipulated based on
the amount of aqueous phase and the generally aqueous phase is maintained at a level where the
entire mixture is an optically transparent microemulsion. The aqueous phase also dictates the
particle size, with an increased amount of water larger nanoparticles are obtained. Like any type
of nanoparticle system the maximum drug loading varies between different therapeutic agents,
but reverse micelles maximum drug loading can be found by gradually adding drug until the
clear microemulsion is converted into a translucent solution. The next step is to add a crosslinking agent under constant stirring and mix overnight to allow for complete cross-linking to
occur. A transparent dry mass is collected by evaporating the organic solvent, after which the
mass is dispersed in water and an appropriate salt is added to precipitate out the surfactant. The
mixture is then centrifuged in order to collect the drug loaded nanoparticles. Finally after being
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re-suspended in aqueous solution it is immediately dialyzed through a dialysis membrane for
approximately 1 h and the liquid is freeze dried leaving a dry powder.
3.1.4 Ionotropic Gelation
Ionotropic gelation is a process where a polyelectrolyte is cross-linked with a counter ion
forming a hydrogel. The structures of hydrogels are maintained by hydrogen bonding,
hydrophobic forces, ionic forces or molecular entanglements [69]. This technique has been
applied using a variety of materials, including gellan gums, alginates, carboxymethyl cellulose
and chitosan, to create micro and nanoparticles for encapsulation and controlled release of
therapeutic agents [70]. Depending on the material used, the strength of the counter ion and the
desired particle size several methods of ionotropic gelation can be applied, including syringe
dropping and air atomization for bead formation [70], and flush mixing for nanoparticles
formation [63]. The application of ionotropic gelation, which utilizes chitosan’s positive charge
to cross-link it with an anion, to form micro- and nanoparticles has garnered much attention
because the process is very simple and takes place under mild conditions. The mild conditions
refer to the lack of possible toxic reagents and other undesirable effects associated with chemical
cross-linking when compared to reversible physical cross-linking by electrostatic interaction.
The most well documented chitosan nanoparticles produced through ionotropic gelation are
chitosan-tripolyphosphate nanoparticles, which many research groups have explored as a
potential drug delivery system for various drugs [63, 64]. Potential anions are TPP, sodium
alginate, κ-carrageenan and hexadesyl sulphate. When applying the ionotropic gelation process
to chitosan it is first dissolved in aqueous acidic solution, obtained using acetic acid, which
generates the chitosan cations. The chitosan solution is added drop wise under constant stirring
to polyanionic solution (ie.TPP), which through the ionic interaction between the oppositely
charged species, chitosan precipitates to form spherical particles.
Fernandez-Urrusuno et al. prepared insulin loaded chitosan-TPP nanoparticles by adding
insulin to the TPP solution prior to mixing with the chitosan solution [63]. The studied used two
different molecular weight chitosans and the chitosan to TPP mass ratio used was 6:1. The
resulting nanoparticles had a mean particle size between 300–400 nm, a surface charge between
+25 to +54 mV and insulin loading as high as 55%. Another group investigated the intestinal
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absorption of insulin in vivo when delivering using chitosan-TPP nanoparticles [71]. The
intention was to determine if the bioadhesive properties of chitosan would further enhance
insulin’s intestinal absorption. The insulin-loaded chitosan-TPP nanoparticles were prepared
through ionotropic gelation producing particles that were positively charged, had a particle size
between 250– 400 nm, polydipsersity less than 0.1 and an insulin association of up to 80%. The
insulin loaded chitosan-TPP nanoparticles were orally administered to alloxan-induced diabetic
rats and through monitoring the plasma glucose levels the intestinal adsorption of insulin was
tracked. The chitosan-TPP nanoparticles improved the intestinal absorption of insulin more than
aqueous solution of chitosan in vivo and after administration of nanoparticles with 21 I.U/kg of
insulin hypoglycemia was prolonged over 15 hrs. The average pharmacological bioavailability
relative to SC injection of insulin solution improved 14.9%. The in vitro release experiments
indicated an initial burst effect, which is pH-sensitive. Another study would go on to the show
that insulin encapsulation efficiency is highly dependent on the pH with encapsulation
efficiencies ranging between 2 and 85%, with the highest obtained at a pH of 6.1 [72]. This study
also showed that the release of insulin was pH dependent.

3.2 Drug Delivery Applications of Chitosan Nanoparticles
As mentioned in the introduction, chitosan has been used in a large number of drug
delivery systems covering a variety of applications with different therapeutic goals and
application regions of the human body. Chitosan nanoparticles have for the most part contributed
to drug delivery research in the fields of cancer therapy, gene delivery and ocular delivery. One
example of their application to cancer therapy is the previously mentioned gadopentetic acid
delivery system that was used for delivery to tumour sites for gadolinium neutroncapture therapy
[68]. Another cancer therapy system that was explored is chitosan nanoparticles loaded with
doxorubicin-dextran conjugate, which showed reduced side-effects and increased therapeutic
efficiency on solid tumours [73].
Gene therapy or gene delivery involves plasmid DNA being introduced to specific cells,
where through the transcription and translation processes the genetic information is used to
produce the desired proteins. This process, otherwise known as transfection, is challenging and
must overcome several obstacles before the desired results can be obtained. The first challenge in
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gene delivery is successfully targeting the specific type of cells that require transfection. Once,
the desired cells have been reached the delivery system must transport the plasmid DNA through
the cell membrane. The DNA delivery system must avoid uptake and degradation by
endolysosomes and the final challenge is to navigate intracellular trafficking to the nucleus. As
mentioned in the coacervation/precipitation section, chitosan and negatively charged DNA can
interact ionically to form nanoparticles, which provide better protection for DNA against
nuclease degradation and increase transfection efficiency [66, 67]. A more recent study on the
oral application of chitosan nanoparticles for delivery of DNA demonstrated a 5 fold increase in
nanoparticle transport through the M-cell co-culture model when compared to transport through
intestinal epithelial monolayers and that the addition of surface modifiers, in this study
transferrin, increases the transport 3-5 fold [74].
Delivery of therapeutic agents to the ocular region is another area of interest for chitosan
nanoparticles. A study focusing on the delivery of the immunosuppressant cyclosporine A to the
ocular region applied chitosan nanoparticles with a mean size of 293nm and surface charge of
+37mV for their purposes [75]. This study found that in vivo experiments applying cyclosporine
A loaded chitosan nanoparticles in a topical manner to the ocular region of rabbits, produced
therapeutic concentrations in external ocular tissues during at least 48 hours, while maintaining
negligible cyclosporine A concentrations in the inner ocular structures, blood and plasma. This
showed an improvement over chitosan solution containing cyclosporine A and an aqueous
cyclosporine A suspension. This shows great potential for applications in ocular drug delivery.

3.3 Conclusions
Chitosan is a polysaccharide with tremendous upside and beneficial characteristics
making it of great interest to the field of drug delivery. There are several methods of chitosan
nanoparticle production that produce a variety of nanoparticles with different physical and
chemical characteristics, which allows for tailoring to specific drugs and applications. Within the
last 2 decades chitosan nanoparticles have already shown many positive results within a wide
variety of drug delivery applications. Many areas of drug delivery are still showing interest in
chitosan microparticles, so with the inherent advantages of nano-drug delivery systems,
exploration into the nano field is the logical next step.
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The methods of emulsion-droplet coalescence and reverse micelles require the use of
cross-linking agents or other undesirable compounds that make them non-ideal for the purposes
of this study. The coacervation/precipitation method of chitosan nanoparticle production did not
apply potentially harmful chemicals, but the nanoparticles created with this method had low
stability, which was displayed by their zeta potential (<30mV) and the 100% release of the
therapeutic agent in the first 24 hours. In the end, ionotropic gelation was selected as the method
of nanoparticle production for this study because of the process’s mild operating conditions,
simplicity and previous encapsulation results with other therapeutic agents.
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Chapter 4
4 Materials and Methods
4.1 Materials
4.1.1 Chemicals and Equipment
Table 4-1: List of chemicals used during this research study.

Chemicals
Acetic Acid

Catalogue Number
Cat. No. 320099

Supplier
Sigma-Aldrich, Canada

Carrageenan

Cat. No. C1013

Sigma-Aldrich, Canada

Chitosan, Low Molecular

Cat. No. 448869

Sigma-Aldrich, Canada

Chitosan, High MW

Cat. No. 419419

Sigma-Aldrich, Canada

Chitosan, Medium MW

Cat. No. 448877

Sigma-Aldrich, Canada

Glycerol

Cat. No. G7893

Sigma-Aldrich, Canada

Phosphate Buffered Saline

Cat. No. P5368

Sigma-Aldrich, Canada

Potassium Chloride (KCl)

Cat. No. P9541

Sigma-Aldrich, Canada

rHu-Erythropoietin

EPREX

Jansen Ortho, Canada

Sodium Hydroxide (NaOH)

Cat. No. 221465

Sigma-Aldrich, Canada

Sodium Tripolyphosphate

Cat. No. 238503

Sigma-Aldrich, Canada

Weight (MW)

Note: The low MW chitosan was from shrimp shells, 80-85% deacetylated and had a viscosity of
20-200cP at STP. The medium MW chitosan was from crab shells, 75- 85% deacetylated and
had a viscosity of 200-800cP at STP. The high MW chitosan was from shrimp shells, 70-80%
deacetylated and has a viscosity of 800-2000cP at STP. The sodium tripolyphosphate was
technical grade with 85% purity. The carrageenan used was a gel formation grade,
predominantly κ and lesser amounts of λ carrageenan. The rHu-EPO used was clinical grade
EPREX, which had a concentration of 40000IU/mL and came in a 1mL prefilled syringe.
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Table 4-2: List of equipment used during this research study.

Equipment
Balance

Model
PB3002

Balance, Precision

BP 210S

Centrifuge, Ultra

Sorvall WX100

Centrifuge, Ultra

Optima Max, Benchtop

Fluorometer

Fluorolog3

Magnetic Stirrer, Multiple
Magentic Stirrer, Single

Multi-position Magnetic
Stirrer, (Cat. No. 12621-034)
Thermix Stirrer, 120MR

pH Meter

Symphony, SB70P

Transmission Electron
Microscopy (TEM)
Vortex Mixer

CM 10

Water Purifier

MegaPure, MP-3A

Zetasizer

ZetaPlus with ZetaPals

Vortex-Genie

Supplier
Mettler Toledo Inc.,
Columbus, OH, USA
Satorius AG,
Mississauga, ON, Canada
Thermo Fisher Scientific,
Waltham, MA, USA
Beckman Coulter,
Mississauga, ON, Canada
Horiba Jobin-Yvan,
Edison, NJ, USA
VWR International,
Mississauga, ON, Canada
Thermo Fisher Scientific,
Waltham, MA, USA
VWR International,
Mississauga, ON, Canada
Koninklijke Philips
ElectronicsN.V., Netherlands
Thermo Fisher Scientific,
Waltham, MA, USA
Labequit Ltd.,
Markham, ON, Canada
Brookhaven Instruments Corp.,
Holtsville, NJ, USA

4.1.2 Description of Important Chemicals
The important chemicals, EPO and chitosan were previously described in the Chapters 1
and 3. Both chitosan and EPO are amphoteric proteins, also known as zwitterions, meaning that
they contain functional groups with both positive and negative charges. The pH of the
surrounding environment dictates the level of protonation of their functional groups, which
controls the molecules’ net charge. The pH at which the molecule has no charge or the charge of
the positive and negative groups cancels out is known as the isoelectric point. For pH levels
below the isoelectric point of a protein the net charge of the molecule is positive, while for pH
levels above the isoelectric point the protein’s net charge is negative. As mentioned previously,
there is a desire to maintain opposite charges between chitosan and rHu-EPO, in order to
preserve an electrostatic affinity between the two proteins and hopefully increase encapsulation
efficiency. The isoelectric points of chitosan and rHu-EPO are at pH ~6.5 and pH ~4.3,
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respectively. The net charge of the important chemical components as a function of pH is
described in Table 4-3.
Table 4-3: Main chemical components' net molecular charge as a function of pH.

Chemical Component

Net Charge of the Molecule
pH < 4.3

4.3 < pH < 6.5

pH > 6.5

Carrageenan

-

-

-

Chitosan

+

+

No longer
water soluble

rHu-EPO

+

-

-

TPP

-

-

-

The other two major nanoparticle components were sodium tripolyphosphate and
carrageenan. Sodium tripolyphosphate is a white, water-soluble, granular powder and is the
sodium salt of triphosphoric acid. It is produced through the combination of monosodium
phosphate and disodium phosphate under strict environmental conditions. TPP is a component of
commercial detergents, with the purpose of improving surfactant efficiency, and is used in the
preservation of foods for maintaining moisture [76]. TPP has been found to be non-carcinogenic
and have low toxicity, with an oral LD50 of 3900mg/kg, according to the MSDS.
Carrageenan refers to a family of gel-forming polysaccharides that are extracted from red
seaweeds, with the most important being ι-, κ- and λ-carrageenan. ι- and κ- carrageenan are
known as gel-forming carrageenans, while λ-carrageenan is used as a thickener. Carrageenans
are used primarily in the food industry as gelling, thickening and stabilizing agents, but have also
found applications in the pharmaceutical and cosmetics industries. Structurally carrageenans are
composed of a linear galactose backbone with sulphatation range between 15 and 40%; however,
carrageenan is mixture of linear, sulphated, water-soluble galactans rather than one biopolymer.
Carrageenans consist of alternating 3-linked β-D-galactopyranose (G-units) and 4-linked α-Dgalactopyranose (D-units) or 4-linked 3,6-anhydrogalactose (DA-units) repeating units [77].
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Figure 4-1: Structure of sodium tripolyphosphate.

Figure 4-2: Structure of κ-, ι- and λ- carrageenan.
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4.2 Methods
4.2.1 Preparation of Chitosan Nanoparticles
Chitosan stock solutions were prepared by dissolving chitosan in 2% (w/v) acetic acid
solution and allowing 12 hours for mixing. The chitosan solution was then filtered through 8µm
filter paper using a vacuum system in order to remove any undissolved chitosan. The pH of the
stock solution was then adjusted to a pH of 5 using sodium hydroxide.
4.2.1.1 Chitosan-TPP Nanoparticles
Chitosan solutions of 0.5mg/mL, 1mg/mL, 1.5mg/mL, 2mg/mL and 3mg/mL were
prepared by diluting stock solution with Milli-Q purified water. The solutions’ pH levels were
adjusted to pH 5 using 10N sodium hydroxide. Sodium tripolyphosphate was dissolved in MilliQ purified water to produce a stock solution with a concentration of 1mg/mL. Based on the
chitosan concentration being used TPP solutions that would yield a final chitosan to TPP mass
ratio of 3:1, 4:1, 5:1, 6:1 and 7:1 were prepared. The chitosan-TPP nanoparticles were generated
through flush mixing of 5mL of chitosan solution with 5mL of TPP solution of equal pH at room
temperature and allowed to mix for 30 minutes. Triplicates of each chitosan concentration and
chitosan to TPP mass ratio combination were performed.
4.2.1.2 Chitosan-Carrageenan Nanoparticles
Chitosan solutions of 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 1mg/mL and 2mg/mL were
prepared by diluting stock solution with Milli-Q purified water. The solutions’ pH levels were
adjusted to pH 5 using 10N sodium hydroxide. Carrageenan was dissolved in Milli-Q purified
water to produce a stock solution with a concentration of 1mg/mL. Based on the chitosan
concentration being used carrageenan solutions that would yield a final chitosan to carrageenan
mass ratio of 2:1, 3:1, 4:1, 5:1 and 6:1 were prepared. The chitosan-carrageenan nanoparticles
were generated through flush mixing of 5mL of chitosan solution with 5mL of carrageenan
solution of equal pH at room temperature and allowed to mix for 30 minutes. Triplicates of each
chitosan concentration and chitosan to carrageenan mass ratio combination were performed.
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Figure 4-3: Schematic diagram of chitosan nanoparticle production through ionotropic gelation.

4.2.2 Chitosan Nanoparticle Physiochemical Characterization
The mean effective diameter, particle size distribution and zeta potential of the chitosan
nanoparticles were determined using the ZetaPlus zetasizer produced by Brookhaven Instruments
Corp. The mean effective diameter and polydipsersity (particle size distribution) were
determined for each sample using dynamic light scattering (DLS) with the temperature
maintained at 20°C and 10 single measurement runs of 30 seconds in length were performed
using a detection angle of 90° and a refractive index of 1.335. Laser doppler electrophoresis
(LDE) was applied to determine the nanoparticle zeta potential of each sample with the
temperature maintained at 20°C, a refractive index of 1.335 and dilution with 1mM KCl for the
10 runs conducted per reading. The nanoparticle solution was diluted by 15 times and the diluted
solutions had a pH of 5.5±0.1.
4.2.2.1 Dynamic Light Scattering (DLS)
Dynamic Light Scattering, also known as Quasi-Elastic Light Scattering (QELS), is a
technique applied to determine the average particle diameter, particle size distribution and
polydipsersity index of particle dispersions. DLS measures the Brownian motion, the random
movement of particles caused by the barraging of solvent molecules, in order to calculate the
particle size. The Brownian motion of larger particles is less than that of smaller particles, since
the collision of other molecules with smaller particles produces a greater transfer of energy; thus,
more of a reaction. Typically DLS is applied to colloidal systems with particle diameters ranging
between 3nm to 3µm, since these particles have the ability to remain suspended within solution,
which means more importance is placed on dispersion than gravitational sedimentation. The
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temperature must be known and maintained stable because the viscosity, which is temperature
dependent, is critical for the determination of particle size through DLS.
Equation 4-1

The Stokes-Einstein equation (Eq. 4-1) can be used to calculate the hydrodynamic
diameter of a particle in solution using the transitional diffusion coefficient (D), the Boltzmann’s
constant (κ), absolute temperature (T) and the viscosity (η) [78, 79]. The translational diffusion
coefficient is a property used to define the velocity of Brownian motion. The diameter computed
using the Stokes-Einstein equation is the diameter of a sphere with the same transitional
diffusion coefficient as the particle. DLS determines the speed of Brownian motion of particles

Correlation Coefficient

within a colloidial system by measuring the rate of fluctuation in intensity of scattered light.
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Figure 4-4: Typical correlogram from a sample containing large particles and a sample containing small particles. The
signal correlation is seen to decay more rapidly for the sample of small particles.

The rate of fluctuation in intensity of scattered light is dependent on the particle size, with
smaller particles causing the intensity to fluctuate more quickly than larger particles. Although, it
is possible to directly determine the intensity fluctuations through measurement of their spectrum
of frequencies, it is more efficient to use digital auto correlators. A correlator compares the
correlation between signal intensity measurements over time, where a perfect correlation is 1
(known as unity) and no correlations is denoted by 0. The larger the particles in the colloid
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system the slower the signal changes with time and the longer the correlation persists (Fig. 4-4).
The correlogram for a sample contains a considerable amount of information with the starting
point of significant decay being connected to the mean particle size and the slope of decay being
related to sample polydispersity. The greater the slope of the correlogram for a sample the more
monodisperse it is. The correlation function (Eq. 4-2) is used to convert the intensity signals into
a measurement of the translational diffusion coefficient. Equation 4-2 is the correlation function
for a suspension of large monodisperse globular particles, where A is an optical constant set by
the design of the instrument, B is the intercept of the correlation function, Γ is related to the
relaxation of the fluctuations and τ is time delay [78, 79]. The correlation function is constructed
by the DLS software for polydisperse samples by replacing the term e-2Γτ with the sum of all the
exponential decays within the correlation function.
Equation 4-2

Equation 4-3

Equation 4-4

Equation 4-5

In Equation 4-4, q represents the scattering vector, n represents the refractive index of the
dispersant, λ represents the wavelength of the laser and θ represents the scattering angle.
Through the combination of Equations 4-2, 4-3 and 4-4 the translational diffusion coefficient is
determined and then substituted into the Stokes-Einstein equation to calculate the particle
diameter. Variance in the correlation function is given in the form of the polydispersity index,
which indicates the particle size distribution. In Equation 4-5, µ is a value proportional to the
variance of the weighted translational diffusion coefficient distribution and it carries information
about the width of the particle size distribution that is made useful through conversion into the
polydispersity index [78, 79].
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Figure 4-5: Schematic diagram of a DLS instrument comprised of 1) laser, 2) attenuator, 3) sample cell, 4) thermostat, 5)
photomultiplier, 6) autocorrelator and 7) analyzing computer.

A DLS device operates by directing a constant wavelength laser beam through a cuvette
containing sample (sample cell), whose temperature is maintained constant by a thermostat (Fig.
4-5) [79]. The laser beam is then scattered by the colloidal particles and the scattered light is
detected by either a photomultiplier tube (PMT) or a photodiode at an angle of θ (90° for
ZetaPlus). If the intensity of scattered light is too great the detector will become saturated or if
there is too little scattered light for detection measurement will not be possible, which is why an
attenuator is used to adjust the amount of scattered light to within an acceptable range. The
detected information is subsequently sent to the correlator and analytical computer for
processing. Figure 4-6 is an example of the typical chitosan nanoparticle measurement obtained
using the DLS technique and the ZetaPlus instrument.

Figure 4-6: Typical lognormal distribution for chitosan-TPP nanoparticles. Medium MW chitosan, chitosan
concentration of 0.5mg/mL, chitosan to TPP mass ratio of 3:1, T= 20±1°C and pH 5.
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4.2.2.2 Laser Doppler Electrophoresis (LDE)
Laser Doppler Electrophoresis is a method of determining the zeta potential of particles
in solution through the measurement of the drift velocity of a colloid in a known electric field.
Almost all particles dispersed in a liquid have a charge that will cause them to move towards
either the positive or negative pole of an applied electric field (electrophoresis) with the direction
of movement indicating the sign of the charge. While, the velocity with which the particles travel
towards the pole is indicative of the magnitude of the charge. LDE measures both the direction
and velocity of particle movement within an electric field and then calculates the mobility and
zeta potential.
There are four electrokinetic phenomena that affect colloidal dispersions:
electroosomosis, electrophoresis, sedimentation potential and streaming potential. In the
ZetaPlus only electrophoresis is considered, since the other variables are eliminated, which
provides an advantage over other methods that must consider multiple electrokinetic phenomena.
During electrophoresis the particles move toward the oppositely charged electrode with an
average drift velocity (Vs), which is proportional to the electric field strength when the field
strength is low (Eq.4-6) [80, 81]. The mobility (µe) of a particle is indicative of the surface
charge with a positive mobility meaning the charge is positive and a negative mobility meaning
the charge is negative. The sign of mobility is important, but the value itself does not provide any
information on the repulsive surface forces. However, there is no independent way of calculating
zeta potential without mobility using the electrophoresis technique.
Equation 4-6

Equation 4-7

Equation 4-8
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There are two models, the Smoluchowski and the Huckel equations, relating mobility and
zeta potential (ζ) that can be used within certain limits. The Huckel equation can only be applied
when the dimensionless product κa, where a is the particle radius and κ-1 is the double layer
thickness, is much less than one and is useful for applications with ions (Note: κ-1 is large at low
electrolyte concentrations and small at high electrolyte concentrations). The Smolunchowski
equation (Eq. 4-7) is applied when κa is much larger than one, but this condition is not easily
fulfilled by colloids either, so a general equation exists as well (Eq. 4-8) [80, 81]. Both equations
involve the relative permittivity of the liquid (ε) and liquid viscocity (η). In practise generating
the function and applying the general equation is too complex; thus, the ZetaPlus software
utilizes the Smolunchowski equation for converting mobility into zeta potential.

Figure 4-7: Schematic diagram of the ZetaPlus electrode comprised of gold electrodes for electric field production, a
thermistor for temperature control, and a PC Board and connector unit for information transfer (Adapted from Weiner
et al., 1993).

In order to apply the aforementioned equations to calculate the mobility and zeta
potential, the average drift velocity of the particles must be measured first. The ZetaPlus
measures the average drift velocity by directing a laser beam through the sample cell, where two
electrodes (Fig. 4-7) generate an electric field. The light is scattered by the particles, moving
perpendicular to the laser beam towards the poles of the electric field, causing a Doppler shift in
the frequency of the scattered light. The frequency of the light is shifted proportionately to the
velocity of the particles and contains information on the particle mobility. A part of the laser
beam is diverted before reaching the sample cell with the purpose of creating a reference beam
and is recombined with the scattered light leaving the sample cell. The purpose of the reference
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beam is to determine the sign of the zeta potential by ascertaining whether the Doppler shift was
positive or negative. Frequency is an intrinsically positive value, so the Doppler shift is
compared to the reference beam with Doppler shifts larger than the reference beam resulting
from positively charged particles and shifts less than the reference beam resulting from
negatively charged particles. Most Doppler shifts are within the range of 100Hz and the ZetaPlus
reference beam is 250Hz. The average drift velocity is calculated using Equation 4-9, where n is
the liquid refractive index, λ is the wavelength of the laser, θ is the scattering angle and ωD is the
Doppler shift frequency [80, 81].
Equation 4-9

The design of the ZetaPlus zetasizer is depicted in Figure 4-8. First a laser generates a
beam of light that is split with 90% of the beam being directed towards the sample cell and the
other 10%, directed past the sample cell, becoming the reference beam. The beam passes through
the sample cell in which the particles are moving perpendicular to the beam due to the electrode
induced electric field. The light that is scattered at an angle of 15° is collected and combined
with the reference beam, which is then measured by a PMT detector that sends the measurement
to an analysis computer. An example of the typical chitosan-TPP nanoparticle zeta potential
measurement obtained through LDE using the ZetaPlus zetasizer is shown in Figure 4-9.
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Figure 4-8: Schematic diagram of ZetaPlus zetasizer comprised of 1) the laser, 2) the lens, 3) the beam splitter, 4) a
mirror, 5) the sample cell and electrodes, 6) a mirror, 7) the beam combiner and 8) the PMT detector (Adapted from
Weiner et al., 1993).
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Figure 4-9: Typical zeta potential measurement for chitosan-TPP nanoparticles. Medium MW chitosan, chitosan
concentration of 0.5mg/mL, chitosan to TPP mass ratio of 3:1, T= 20±1°C and pH 5.

4.2.3 Particle Morphology – Transmission Electron Microscopy
The chitosan nanoparticle morphology was determined using transmission electron
microscopy with a CM 10 (Phillips, Netherlands). A single drop of chitosan nanoparticle
solution was placed on a formvar/carbon 400 mesh grid and allowed to air-dry at room
temperature for 1-2 minutes before analysis at 80kV.
TEM is a popular method for viewing and imaging solid materials at the atomic level.
The general design is similar to that of an optical microscope; however, instead of light high
energy electrons are used and rather than glass lenses electromagnetic lenses are used. TEM
systems are able to obtain a spatial resolution of approximately 0.1nm and typically operate at
electron voltages of 80-120kV for conventional 2D imaging, while 150-400kV can be applied for
electron tomography, energy filtered TEM and cryoTEM [82]. The basics of TEM are that an
electron beam generated by a cathode and accelerated by an anode passes through a sample, the
output pattern is magnified using a system of lenses and then the image is displayed on a
fluorescent screen or a charge-couple device camera.
The microscope consists of an electron gun at the top of an extended cylindrical column
followed by two electromagnetic condenser lenses, one that focuses the electron beam and
another lens for fine adjustments (Fig. 4-10). These first two lenses allow for control over
brightness of the beam. The beam then passes through the condenser aperture and hits the
sample. Electrons that hit the sample are either diverted (elastic electrons) or adsorbed by the
sample material. The elastically scattered electrons travel through the objective lens, which
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forms the image of the sample that then passes through the objective aperture onto the
magnification system. There are three lenses that compose the magnification system, the first
two magnify the image and the final lens, the projector lens, projects the image onto either a
fluorescent screen or a charge-couple device camera. The microscope column is maintained
under vacuum while operating.
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Figure 4-10: Schematic diagram of a TEM instrument comprised of 1) an electron gun, 2) electron beam, 3) condenser
lenses, 4) condenser aperture, 5) sample, 6) objective lens, 7) objective aperture, 8) magnification system and 9)
fluorescent screen or charge-couple device camera (Adapted from Kuo, 2008).

4.2.4 Statistical Analysis
Response surface modeling is a method of statistical experiment design that allows for
the determination of peak process performance [83]. This statistical method of experimentation
has been applied to both industrial and academic applications to produce accurate process maps
based on mathematical modeling. The advantage of RSM is that it allows for several factors to
be varied at a time, rather than the traditional one-factor-at-a-time (OFAT), which reduces
experimental trials, time and cost. Screening experiments allow for the development of a broad
view of the various factors affecting the process, while response surface modeling allows for a
close up view of areas of interest with the goal of process optimization.
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RSM allows for a full quadratic model to be generated with a lower number of
experimental trials than would usually be required. The most commonly used response surface
design methods are the Box-Behnken design (BBD) and the Central Composite design (CCD),
although when these prove insufficient then computer generated designs, referred to as optimal
designs, may be explored. The CCD consists of a two-level factorial design with center points, as
well as axial points that provide the additional information needed to determine curvature (Fig.
4-11). A popular type of CCD is the face centered cubic design (FCC), which has axial points
that do not extend beyond the area of interest. The distance beyond or within the selected range
of conditions that axial points extend is determined by the chosen α value, where for an α value
equal to one the axial points are at the edge of the domain and for an α value greater than one the
axial points extend beyond the domain. BBDs combine two-level factorial design with an
incomplete block design with center points. The BBD requires a fewer number of trials than
CCD; however, this method may produce areas of poor prediction.

Figure 4-11: Orientation of points for trial conditions when considering a three factor design a) Central Composite Design
b) Face Centered Cubic Design (CCD with α = 1) c) Box-Behnken Design. Black dots represent factorial points, dark blue
dots center points and light blue dots axial points.

For the purposes of this study a full FCC design (α=1) was selected, since it was
determined that experiments beyond the area of interest, for both chitosan-TPP and chitosancarrageenan nanoparticles, would not follow the trends within the area of interest and thus an α
greater than one would not add any value to the design. The FCC designs created focussed on
three factors, which resulted in 15 different experimental conditions that were tested in triplicate.
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4.2.5 Encapsulation of rHu-Erythropoietin
Encapsulation involved the mixing of 100µL of 40000IU/mL (~308µg/mL) rHu-EPO
with 5mL of chitosan solution for 30 minutes before continuing the production process (4.2.1).
The optimal conditions for chitosan-TPP and chitosan-carrageenan nanoparticle production were
determined using RSM and chitosan MW studies were conducted under these conditions. The
chitosan MW studies compared the encapsulation efficiency of low, medium and high MW
chitosan. Besides the effect of chitosan MW, the effect of nanoparticle surface charge on the
encapsulation efficiency of chitosan-TPP and chitosan-carrageenan nanoparticles was also
analyzed through manipulation of production conditions using RSM. Table 4-4 displays the
production conditions for each of the trials completed and each trial was performed in triplicate.
The drug-loaded nanoparticles were centrifuged at 38200rpm (100000 x g) and 4°C in a Sorvall
Ultra Centrifuge with a Sorvall T-1270 Rotor for 30 minutes. After which the encapsulation
efficiency was established by measuring the fluorescence of the supernatant (4.2.7). The
encapsulation efficiency of each trial was calculated using Equation 4-10.
Equation 4-10

Table 4-4: Nanoparticle production conditions for encapsulation and controlled release studies.

Chitosan-TPP Nanoparticles
Trial
CS Concentration
(mg/mL)
i
0.6
~40mV CS-TPP NPs
0.68
~35mV CS-TPP NPs
0.65
~30mV CS-TPP NPs
Chitosan-Carrageenan Nanoparticles
Trial
CS Concentration
(mg/mL)
i
0.5
~50mV CS-TPP NPs
0.5
~45mV CS-TPP NPs
0.8
~40mV CS-TPP NPs

CS:TPP Mass Ratio

Solution pH

4:1
3.8:1
3.7:1

5.2
5.5
5.85

CS:CG Mass Ratio

Solution pH

3:1
3:1
5:1

5
5.5
5.5

i These conditions represent the optimized conditions as well as the those used during the chitosan MW studies.
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4.2.6 Controlled Release of rHu-Erythropoietin
The drug-loaded nanoparticles from the encapsulation study were re-suspended in 1mL
of pH 7.4 phosphate buffered saline (PBS) solution and placed in a shaker set at 150rpm and
37°C. These conditions were selected in order to simulate the stresses that the nanoparticles
would be subjected to in the human body. Periodically the samples were removed and
centrifuged at 40000rpm (75000 x g) for 30 minutes in an Optima Max Benchtop with a MLA130 rotor. Fresh PBS solution was added, the samples were vortexed for 2 minutes and the
release study was continued.
4.2.7 Fluorometer Measurement
The rHu-EPO concentration was measured using fluorometric assay, which is based on
the presence of 3 tryptophan residues present in rHu-EPO that are fluorescent. A Fluorolog3
instrument was used to measure the fluorescent intensity of the 800µL of sample aliquots. The
intensity measurements were converted into concentration values through application of a
standard curve. The excitation wavelength was set to 280nm and the light emission was
measured over the range of 295-450nm.
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Figure 4-12: Schematic diagram of the Fluorolog3 instrument comprised of 1) a light source, 2) an excitation
monochromator, 3) a sample compartment, 4) an emission monochromator and 5) a detector (Adapted from Jobin, 2002).
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When a molecule absorbs light at a certain wavelength and then reacts by emitting light
at a different wavelength the molecule has fluoresced. This process can be applied for the
purposes of molecular identification and characterization, and imaging by exciting molecules at
known excitation wavelengths, and measuring emission wavelengths and intensity. Fluorometry,
when compared to spectroscopy, provides lower detection limits, since the emission wavelength
does not have any background interference [84].
Fluorometers are relatively simple pieces of equipment consisting of a light source,
monochromator for excitation wavelength selection, a monochromator for emission wavelength
selection, a detector and analysis computer. The design of the Fluorlog3 is displayed in Figure 412. The Fluorolog3 utilizes a 450W xenon lamp with a spectral range of 200-1000nm for sample
excitation. The Fluorolog3 used in this study had single-grating monochromators for both
excitation and emission. The sample is stored in a T-box compartment and the light emission is
measured using a PMT detector unit [84, 85].
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Chapter 5
5 Chitosan Nanoparticle Characterization – Screening Process
As mentioned in the introduction, the chitosan nanoparticle characteristics of interest
were nanoparticle size, surface charge and size distribution. Particle size is a difficult parameter
to define for many nanoparticles because the particle geometry may prevent definition of one or
a few characteristics values, which has led to the use of spherical equivalent diameter. As
mentioned previously, the diameters reported are the hydrodynamic diameters equivalent to a
sphere of the same volume as the particles. The particle size is important to the drug delivery
system’s ability to penetrate tissue and effectively release the therapeutic agent [86]. Desai et al.
[31] explored the effect of size on particle uptake in Caco-2 cells, where 100nm nanoparticles
displayed 2.5 times greater uptake when compared 1µm microparticles and 6 times greater
uptake than 10µm microparticles. Similar results have been observed in vivo, such as the
gastrointestinal track of rats where the uptake of nanoparticles was between 15 and 250 times
greater uptake compared to microparticles and the nanoparticles were able to enter the
submucosal layers, while microparticles remained trapped in the epithelial lining [87,88].
When in an aqueous solution, the area around a particle consists of an electrical double
layer with an outer layer of loosely bound ions (Stern layer) and an inner layer of tightly bound
ions (HelmHoltz layer). Thus, when a particle moves the ions that are bound tightly enough
travel with the particle, while those ions outside this boundary, known as the slipping plane, do
not. The potential difference at this boundary is defined as the zeta potential. Zeta potential is not
the same as the surface charge of the particle, but is reflective of the particle surface charge. The
zeta potential is also representative of the colloidal stability. Colloidal systems with zeta
potentials greater than ±30mV are generally considered stable. By creating nanoparticles of
various zeta potentials the colloidal stability can be controlled, which dictates the particle
longevity and could potentially allow for control over the drug release rate. The surface charge is
also related to the efficiency with which nanoparticles interact with proteins and enzymes within
bodily fluids. The interaction of nanoparticles with lysozyme and their resultant degradation was
shown to have a strong dependence on the surface charge [89]. In order, to maintain controlled
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drug release and avoid being removed from circulation nanoparticles must be able to evade
lysozomal degradation. Nanoparticle interaction with the surrounding environment is not only
important for drug delivery efficiency, but also because of the potential health risks. Some
nanoparticles, such as carbon nanoparticles, have been shown to affect the aggregation of human
platelets, which can lead to vascular thrombosis. Recent research into the effect of chitosanPLGA nanoparticles on platelet aggregation suggests that the application of chitosan
nanoparticles in concentrations below 10µg/mL does not alter platelet aggregation [90].
The particle size distribution was investigated through the measurement of the unit less
parameter polydispersity. Polydispersity is a measure of uniformity with 0 being perfectly
uniform. When considering colloids a polydipsersity value between 0 and 0.02 is called
monodisperse and a value between 0.02 and 0.08 is considered a narrow distribution. Uniform
particle size distribution is important to maintaining a consistent drug release rate and therefore
should be minimized. Achieving a narrow distribution is challenging and monodisperse
distributions have only been observed in nature.

5.1 Screening Characterization of Chitosan-TPP Nanoparticles
The first step in this study was to determine the effects of chitosan concentration,
chitosan to TPP mass ratio, solution pH and chitosan MW by performing screening experiments
to provide an overview of the nanoparticle production process. For each concentration of
chitosan solution an equal volume TPP solution was added to create final chitosan to TPP mass
ratios of 3:1, 4:1, 5:1, 6:1 and 7:1; while a pH of 5 was maintained. The chitosan-TPP
nanoparticle diameter was shown to increase with increasing chitosan concentration and to
generally increase with an increase in the chitosan-TPP mass ratio for the range of parameters
tested (Fig. 5-1). The nanoparticle diameter increased in a linear fashion for all chitosan
concentrations used for mass ratios of 3:1, 4:1 and 5:1 (Fig. A-1); however, for the chitosan
concentrations of 1.5mg/mL and 2mg/mL the diameter plateaued after these mass ratios. This
plateau may be the result of decreasing anion concentration, which then neutralizes the anion
attractive forces halting particle growth. Also, at the higher chitosan to TPP mass ratios of 6:1
and 7:1, and at certain concentrations large unstable aggregates formed rather than the desired
nanoparticles.
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The screening experiments demonstrated that the surface charge decreased in a linear
manner with an increase in chitosan concentration, while increasing as the chitosan to TPP mass
ratio rose (Fig. 5-2, Fig. A-2). These trends did not hold for the mass ratios of 6:1 and 7:1 for
reasons previously stated. The zeta potential measurement was positive for all nanoparticles
formed, which is to be expected due to the positive charge of chitosan and is consistent with the
idea that the nanoparticle structure is mostly composed of chitosan.

Figure 5-1: Effect of chitosan concentration and chitosan to TPP mass ratio on the mean particle diameter of chitosanTPP nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5.

The particle size distribution also followed a linear increase with an increase in chitosan
to TPP mass ratio, while polydispersity demonstrated a minimum at a chitosan concentration of
1.5mg/mL (Fig. 5-3). The nanoparticle size distribution was very broad with polydispersity
values ranging from approximately 0.24 to 0.38. The broad size distribution could be reflective
of chitosan’s broad range of MW, since chitosan is sold in low, medium and high MW, each with
wide distributions. Another option to improve the size distribution profile may be to remove any
impurities [91].
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Figure 5-2: Effect of chitosan concentration and chitosan to TPP mass ratio on the zeta potential of chitosan-TPP
nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5.

Figure 5-3: Effect of chitosan concentration and chitosan to TPP mass ratio on the polydispersity of chitosan-TPP
nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5.
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The effect of pH on the nanoparticle characteristics was explored separately at constant
chitosan concentration and chitosan to TPP mass ratio. The pH levels tested were above 4.5,
since the isoelectric point of rHu-EPO is ~4.3 and it was necessary to maintain a negative charge
on the rHu-EPO molecules, in order to maintain the necessary affinity with positively charged
chitosan later on in the encapsulation and controlled release studies [84]. The pH did not
demonstrate a simple relationship with either the nanoparticle diameter or the polydipsersity;
however, both displayed a minimum at the pH of 5.5 (Fig. 5-4A, B). This minimum in particle
diameter may be observed because of changes to chitosan’s net charge with pH. While the pH is
shifted from 5.0 to 5.5 chitosan’s positive charge decreases, resulting in less TPP incorporation
in the particle structure, which causes the particle size to decrease. Whereas, when the pH
increases from 5.5 to 6.0 further decrease in chitosan’s charge occurs, resulting in reduced
electrostatic repulsion between chitosan molecules and increased chitosan to TPP binding, again
causing larger particles to be formed. The relationship between the pH and zeta potential
appeared to be linear in nature, where a decrease in the zeta potential was observed with an
increasing solution pH, which resulted due to the chitosan attractive forces weakening as the pH
approached its isoelectric point of ~6.5.
The chitosan MW study demonstrated that the MW of chitosan does have an effect on the
particle diameter with an increase in MW producing an increase in particle diameter when using
a chitosan to TPP mass ratio of 3:1 or 4:1 (Fig. 5-5A). Beyond the chitosan to TPP mass ratio of
4:1, the medium MW chitosan generated larger particles than the high MW chitosan, which may
be the result of the high MW chitosan nanoparticles obtaining their maximum size. The high
MW chitosan has significantly longer polymer chains and combined with the decreasing amount
of TPP this means the nanoparticles would no longer have the ionic force required to maintain
particle size growth beyond a certain diameter. This is re-enforced by the decrease in high MW
chitosan nanoparticle diameter as the chitosan to TPP mass ratio decreased. The medium MW
chitosan nanoparticles were able to grow in a manner that allowed for their continued growth
despite the deceasing amount of TPP. The zeta potential analysis supports the particle diameter
results because past a chitosan to TPP mass ratio of 4:1 the medium MW chitosan nanoparticles
have a higher zeta potential than the high MW chitosan nanoparticles (Fig. 5-5B). The plateau in
high MW chitosan nanoparticle zeta potential demonstrates that no further chitosan was able to
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ionotropically gel to the nanoparticles because doing so would have increased the positive zeta
potential of the nanoparticles. For the most part the medium MW chitosan nanoparticles had a
greater polydispersity than the low or high MW chitosan nanoparticles, which was expected
since the medium MW chitosan had a broader range of MW.

Figure 5-4: Effect of pH level on A) the mean particle diameter, B) zeta potential and C) polydispersity of chitosan-TPP
nanoparticles. Medium MW chitosan, chitosan concentration of 1mg/mL, chitosan to TPP mass ratio of 3:1, T= 20±1°C.
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Figure 5-5: Effect of chitosan MW on A) the mean particle diameter, B) zeta potential and C) polydispersity of chitosanTPP nanoparticles. Chitosan concentration of 1mg/mL, pH 5, T= 20±1°C.
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The goal of the screening process was to generate an overview of the chitosan-TPP
nanoparticle formation process so that a more focussed analysis and optimization could be
completed through RSM. The results of the screening process led to the selection of a chitosan
concentration range between 0.5mg/mL and 1.5mg/mL, and a chitosan to TPP mass ratio range
of 3:1 to 5:1 for the RSM. The nanoparticles produced within these conditions are between
100nm and 250nm, which provides the small dimensions desired. The surface charge of the
nanoparticles within these constraints implies they will be stable and agglomerate free, and also
allows for further manipulation and the determination of conditions that minimize the
polydispersity within these parameters.

5.2 Chitosan-TPP Nanoparticle Morphology
Assessment of nanoparticle morphology was conducted using transmission electron
microscopy with the intention of verifying the nanoparticle size and determining shape and
structure. The first image (Fig. 5-6) captures a single chitosan-TPP nanoparticle produced under
the same conditions described above, which resulted in a mean particle diameter of ~160nm
using DLS and is in accordance with the particle size displayed in the image. Previous works
[64] have reported spheroids; however, imaging results (Fig. 5-6 and 5-7) during this study found
no one dominant shape, with spheroids being present as well as more elongated structures. Gan
et al. reported similar results for blank chitosan-TPP nanoparticles, but noted spherical structures
when BSA was encapsulated within the particle structure. These observations are also in
agreement with the spherical particles produced after the encapsulation of insulin within
chitosan-TPP nanoparticles [64] and could mean that the presence of another protein is required
for generation of a more uniform spherical particle shape.
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Figure 5-6: TEM image of a chitosan-TPP nanoparticle produced with medium MW chitosan, chitosan concentration of
1mg/mL, and chitosan to TPP mass ratio of 3:1 at a pH of 5 and T= 20±1°C.

Figure 5-7: TEM image of a group chitosan-TPP nanoparticles produced with medium MW chitosan, chitosan
concentration of 1mg/mL, and chitosan to TPP mass ratio of 3:1 at a pH of 5 and T= 20±1°C.
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5.3 Screening Characterization of Chitosan-Carrageenan Nanoparticles
The study’s initial phase was to broadly investigate the effects of process factors,
chitosan concentration, chitosan to carrageenan mass ratio and solution pH, on the nanoparticle
characteristics of interest through a screening process. Chitosan solutions with a concentration
ranging between 0.125mg/mL and 2mg/mL were added to equal volume carrageenan solutions
that resulted in the chitosan to carrageenan mass ratios of 2:1, 3:1, 4:1, 5:1 and 6:1, while
preserving a pH of 5. The chitosan-carrageenan nanoparticle mean diameter ranged between
~180nm up to ~960nm, with the mean particle diameter increasing with chitosan concentration
(Fig. 5-8). Also shown in Figure 5-8, the particle diameter decreased as the chitosan to
carrageenan mass ratio was increased, with the difference being more pronounced at high
chitosan concentrations. The reduced concentration of carrageenan at the higher mass ratios
appears to be limiting the nanoparticle size. At the lowest chitosan concentration of 0.125mg/mL
production of enough nanoparticles to be measurable stopped at a chitosan to carrageenan mass
ratio of 3:1.

Figure 5-8: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the mean particle diameter of
chitosan-carrageenan nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5.
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Figure 5-9: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the polydispersity of chitosancarrageenan nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5.

The polydispersity of the chitosan-carrageenan nanoparticles ranged between 0.215 and
0.380. It was shown, for the most part, that the polydispersity decreased with an increased
chitosan concentration (Fig. 5-9). The exceptions to this pattern were the combination of higher
chitosan concentrations (1.5mg/mL, 2mg/mL) and low chitosan to carrageenan mass ratios (2:1,
3:1). This could be due to the manner in which chitosan and carrageenan mix in solution at these
higher concentrations and viscosities [92]. Also, the polydispersity generally increased with an
increase in the chitosan to carrageenan mass ratio.
The surface charge of the nanoparticles ranged between ~42mV and ~51mV for the
combinations of chitosan concentration and chitosan to carrageenan mass ratio employed. All of
these were high enough to consider the colloidial systems and the particles within them stable.
The surface charge readings obtained did not demonstrate any consistent trend in zeta potential
with chitosan concentration or chitosan to carrageenan mass ratio; however, there was peak zeta
potential measurement at the chitosan concentration of 0.5mg/mL for almost all the chitosan to
carrageenan mass ratios tested (Fig. 5-10).
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Figure 5-10: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the zeta potential of chitosancarrageenan nanoparticles. Medium MW chitosan, T= 20±1°C, pH 5.

The solution pH was an important factor since the process was dependent on the ionic
complexation of oppositely charge compounds whose charge varies with pH. A pH range
between 4.5 and 6.5 was selected to ensure there would be an affinity between chitosan and rHuEPO in the later, encapsulation and controlled release, phase of the study. The isoelectric points
of rHu-EPO and chitosan are at a pH of ~4.3 and ~6.5 respectively [19, 92]. The nanoparticle
diameter within the pH range tested showed undulation between minimums and maximums (Fig.
5-11A). The particle diameter increased towards a solution pH of 6.5 and beyond this point
aggregation of the nanoparticles occurred. The nanoparticle zeta potential steadily decreased
with an increasing solution pH demonstrating the reduction in affiliation between chitosan and
carrageenan as chitosan’s isoelectric point was approached (Fig. 5-11B).
The chitosan MW study revealed that the MW of chitosan has an effect on the particle
diameter of chitosan-carrageenan nanoparticles with a substantial difference in particle diameter
between low and medium MW chitosan nanoparticles. However, there was no major difference
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between medium and high MW chitosan nanoparticle diameter for the range of conditions tested.
In Figure 5-12A, it can be seen that the particle diameter decreases for both the low and high
MW chitosan nanoparticles as the chitosan to carrageenan mass ratio increases, while a plateau is
reached at a mass ratio of 4:1 for medium MW chitosan. This trend agrees with the earlier results
for chitosan-carrageenan nanoparticle production and suggests the carrageenan concentration is
restricting the nanoparticle size. The polydispersity of the nanoparticles increased for all three
chitosan MWs, but the medium MW chitosan nanoparticles consistently had the greatest
polydispersity, which is expected since medium MW had the broadest range of MW (Fig. 512B). The zeta potential was lower for the low and high chitosan MW nanoparticles than that of
the medium MW chitosan nanoparticles, but the same trend was exhibited (Fig. 5-12C).

Figure 5-11: Effect of pH level on A) the mean particle diameter and B) zeta potential of chitosan-carrageenan
nanoparticles. Medium MW chitosan, chitosan concentration of 0.5mg/mL, chitosan to carrageenan mass ratio of 3:1,
T=20±1°C.
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The RSM requires broad knowledge of the production process, so that an area of interest
can be magnified and further explored, which was achieved through the screening experiments.
The range of conditions chosen for RSM were a chitosan concentration between 0.5mg/mL and
1.0mg/mL, a chitosan to carrageenan mass ratio between 3:1 and 5:1, and a solution pH between
4.5 and 5.5. Within the realm of these conditions the nanoparticle characteristics demonstrated
distinct patterns that through further analysis could lead to their optimization.

Figure 5-12: Effect of chitosan MW on A) the mean particle diameter, B) zeta potential and C) polydispersity of chitosancarrageenan nanoparticles. Chitosan concentration of 0.5mg/mL, pH 5, T= 20±1°C.
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5.4 Chitosan-Carrageenan Nanoparticle Morphology
Like for the chitosan-TPP nanoparticles, TEM was performed on the chitosancarrageenan nanoparticles in order to substantiate the particle size determined through DLS and
to provide information on particle shape and structure. Figure 5-13 shows a single chitosancarrageenan nanoparticle that under the same production conditions generated particles measured
to be ~250nm by DLS, which agrees with the results of TEM. A hexagonal structure was present
in a significant number of the nanoparticles produced and could indicate semi-crystal structure
and growth after ionic gelation induced nucleation (Fig. 5-13 and 5-14). This style of particle
formation has been reported before for the similar process of chitosan-TPP nanoparticle
formation [91], but differs from the results of the only other study on chitosan-carrageenan
nanoparticles which described the shape as spherical-like [93]. These results could suggest that
the chitosan-carrageenan nanoparticles initially begin formation in this style and later some
nanoparticles are caused to deviate from semi-crystal formation or that merely a portion of the
nanoparticles are produced through this process.

Figure 5-13: TEM image of a chitosan-carrageenan nanoparticle produced with medium MW chitosan, chitosan
concentration of 0.5mg/mL, and chitosan to carrageenan mass ratio of 4:1 at a pH of 5 and T= 20±1°C.
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Figure 5-14: TEM image of a group chitosan-carrageenan nanoparticles produced with medium MW chitosan, chitosan
concentration of 0.5mg/mL, and chitosan to carrageenan mass ratio of 4:1 at a pH of 5 and T= 20±1°C.
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Chapter 6
6 Chitosan Nanoparticle Response Surface Modelling
The purpose of creating the RSMs for particle diameter, zeta potential and polydispersity
was to establish a method for the accurate modulation of these nanoparticle characteristics during
the production process. Theoretically the ideal nanoparticles for drug delivery would have the
smallest size, highest surface charge and lowest polydispersity possible; however, depending on
the release mechanism of the drug other combinations of nanoparticle size and surface charge
may be optimal. These models should allow for the production of nanoparticles with specific
responses, so that in turn the response affects on encapsulation and controlled release can be
determined.
The CCD method was chosen since performing the multiple experimental production
runs required was not a limiting factor and the additional accuracy this method provided was
desired. In addition, a FCC design was also used since the area outside of the designated range of
process conditions did not display the same relationships as those within. The data was analyzed
using RSM software for fit of linear, two-factor interaction terms (2FI) and quadratic models
between the design factors and the responses.
The coefficient of determination (R2) is often used as the benchmark for model fit, but
unfortunately it is biased, since simply increasing the order of regression can only increase R2,
especially when using small sample sizes. R2 measures the amount of variation relative to the
mean, which is determined using the sum of the squares relative to zero (SSModel) and sum of
squares relative to the mean (SSCorTotal), as seen in Equation 6-1. The PRESS (predicted residual
sum of squares) and R2Pred (R2 predicted) provide additional information on model fit that cannot
be ignored. PRESS is ascertained by summing the square of the residuals (ei) between the
individual observations and the prediction from the regression model generated without
observation i (Eq. 6-2). The goal is to create a regression model that minimizes the PRESS.
R2Pred is another form of the PRESS, but in a value that is similar to the coefficient of
determination (Eq. 6-3). Unlike the R2, which generally ranges between 0 and 1, R2Pred frequently
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has negative values meaning that the mean value is a better fit than the regression model.
Another value of interest is the adjusted R2 (R2Adj), which provides a less biased measure of fit
than R2 by penalizing model parameters, so that only a substantial improvement in fit will
increase the R2Adj value. In Equation 6-4, n represents the number of samples and p represents
the number of parameters in the regression model. All of the mentioned statistical devices were
used when determining the appropriate model for each process factor.
Equation 6-1

Equation 6-2

Equation 6-3

Equation 6-4

6.1 Chitosan-TPP Nanoparticle RSM
The linear and 2FI models for particle diameter both fit reasonably well based on the R2,
R2Pred, R2Adj values; however, the quadratic model was able to significantly lower the PRESS and
provide a slight improvement in the R2, R2Pred, R2Adj values (Table 6-1). When evaluating the
RSM for zeta potential the quadratic model again was determined to be the best fit due to the
minimization of PRESS. The polydispersity response surface model selection was the most
obvious with the quadratic model providing significant improvements over the other two models
in every category. All three RSMs were plagued by poor results on the lack of fit test, where
significant lack of fit was calculated. This can be a common problem when applying RSM to
laboratory studies because the conditions are under strict control, especially for small scale
research, the pure error may be underestimated leading to a biased lack-of-fit test [83]. In these
situations when all other model statistics and diagnostics are fine the model should be accurate.
However, to ensure RSM accuracy trials within the model range, but not included in model
development, were compared to values predicted by the RSMs and were found to be sufficiently
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accurate. The RSMs developed for particle diameter, zeta potential and polydispersity are
displayed below (Equations 6-5, 6, 7), as well as the units for each term contained within the
equations.
Table 6-1: Chitosan-TPP nanoparticle RSM fit characteristics.

Response
Particle Diameter

Zeta Potential

Polydispersity

Relation
Linear
2FI
Quadratic
Linear
2FI
Quadratic
Linear
2FI
Quadratic

R2 (%)
90.68
94.91
97.50
84.13
95.73
97.56
33.51
36.07
92.46

R2Pred (%)
88.68
93.62
96.04
79.98
94.33
96.03
23.06
16.92
87.88

R2Adj (%)
90.04
94.17
96.91
83.04
95.11
96.98
28.98
26.71
90.67

PRESS
8507.23
4795.73
2978.45
234.57
66.49
46.53
0.0981
0.1060
0.0155
Equation 6-5

Equation 6-6

Equation 6-7

X = Chitosan Concentration (mg/mL) Y = Chitosan:TPP Mass Ratio
Z = Solution pH
The RSM for particle diameter displayed the least amount of curvature of the three
responses; however, the majority of the curvature that was present in the quadratic relationship is
due to the chitosan to TPP mass ratio (Fig. 6-1). The earlier results demonstrating a drop in
particle diameter around a pH of 5.5 were supported by RSM where the model indicated that the
minimum particle diameter of ~98nm would be achieved with a chitosan concentration of
0.5mg/mL, chitosan-TPP mass ratio of 3 and a pH 5.44.
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The RSM generated for colloidal polydispersity exhibits consistent shape throughout the
various solution pH levels and the relationships with chitosan concentration and chitosan-TPP
mass ratio determined by the screening process are predicted as well (Fig. 6-3). The colour
mapping on the surface and contour plots shows that polydispersity has a minimum based on pH,
which the model determined was ~0.16 and would be achieved with a chitosan concentration of
1mg/mL, chitosan-TPP mass ratio of 3:1 and a pH of 5.5.
The RSM for zeta potential expressed a significant amount of curvature with the overall
shape of the response surface changing with the solution pH (Fig. 6-2) and with the 3D surface
plots at the model limits of pH 5 and pH 6 almost resembling mirror images. As the colour
mapping indicates, the zeta potential does indeed decrease with an increase in solution pH, but
the relationship between zeta potential positively correlates with the chitosan concentration.

Figure 6-1: Response surface 3D models and contour plots displaying the relationship between chitosan concentration and
chitosan to TPP mass ratio with the mean particle diameter of chitosan-TPP nanoparticles for the pH values of 5.0, 5.5
and 6.0. Medium MW chitosan, T= 20±1°C.
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Figure 6-2: Response surface 3D models and contour plots displaying the relationship between chitosan concentration and
chitosan to TPP mass ratio with the zeta potential of chitosan-TPP nanoparticles for the pH values of 5.0, 5.5 and 6.0.
Medium MW chitosan, T= 20±1°C.

Figure 6-3: Response surface 3D models and contour plots displaying the relationship between chitosan concentration and
chitosan to TPP mass ratio with the polydispersity of chitosan-TPP nanoparticles for the pH values of 5.0, 5.5 and 6.0.
Medium MW chitosan, T= 20±1°C.
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6.2 Chitosan-Carrageenan Nanoparticle RSM
All three models, linear, 2FI and quadratic, fit the particle diameter data well based on the
R2, R2Pred, R2Adj values (Table 6-2). The PRESS was lower when applying the linear model,
which was one of the reasons for its selection as the model of choice. The principle of parsimony
was the other reason, this principle suggests selecting the simplest of scientific explanations
when selecting between equally accurate solutions. The RSM for zeta potential yielded the
quadratic model the clear cut favourite, since R2, R2Pred, R2Adj values were significantly higher for
this model and the PRESS was minimized. The polydispersity response surface model selection
was between the 2FI and quadratic models, which both had almost identical values, so again the
decision was based on the principle of parsimony to select the 2FI model. Like the results for the
chitosan-TPP nanoparticles, the RSMs for chitosan-carrageenan nanoparticles for particle
diameter and zeta potential exhibited poor lack of fit, but the polydispersity RSM showed no
significant lack of fit. Again, trials within the model range, but not included in model
development, were compared to values predicted by the RSMs and were determined to be
accurate. The RSM for polydispersity had the weakest fit, despite passing the lack-of-fit test, but
was able to provide some guidance as to the potential polydispersity of the samples. However,
due to the lower fit of the model less emphasis was placed on the polydispersity RSM when
optimization of nanoparticle production was performed. The RSMs developed for particle
diameter, zeta potential and polydispersity are displayed below (Equations 6-8, 9, 10), as well as
the units for each term contained within the equations.
Table 6-2: Chitosan-carrageenan nanoparticle RSM fit characteristics.

Response
Particle Diameter

Zeta Potential

Polydispersity

Relation
Linear
2FI
Quadratic
Linear
2FI
Quadratic
Linear
2FI
Quadratic

R2 (%)
95.16
95.22
95.47
76.79
79.42
86.80
63.78
77.50
78.79

R2Pred (%)
94.36
93.89
92.79
72.34
72.55
79.44
54.02
63.83
62.38
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R2Adj (%)
95.16
94.46
94.31
75.09
76.16
83.40
61.13
73.95
73.34

PRESS
4810.03
5212.28
6149.53
199.33
197.78
148.14
0.025
0.020
0.020

Equation 6-8

Equation 6-9

Equation 6-10

X = Chitosan Concentration (mg/mL) Y = Chitosan:Carrageenan Mass Ratio
Z = Solution pH
The linear RSM developed for particle diameter displayed minimum values when the
chitosan concentration was at its lowest and chitosan-carrageenan mass ratio was at its highest
(Fig. 6-4). This result agrees with the data from the screening process (5.3); however, no
minimum was described at the pH of 5 showing that pH has no significant effect within this
range of production conditions. The minimum particle diameter within the range of conditions
tested was determined to be ~260nm and would be achieved with a chitosan concentration of
0.5mg/mL, chitosan-carrageenan mass ratio of 5 and a pH of 5.
The RSM for particle size distribution (polydispersity) did not indicate a significant
relationship with solution pH, as was determined in the screening process, with no considerable
increase or decrease in polydispersity and consistent 3D model shape. However, the relationships
between polydispersity, and chitosan concentration and chitosan-carrageenan mass ratio
displayed are in agreement with those determined in the screening process (Fig. 6-5). As the
selection of the 2FI model implies there was some curvature to the model, which occurred in
both the chitosan concentration and chitosan-carrageenan mass ratio axes.
The zeta potential RSM displayed considerable curvature with the general shape of the
response surface remaining mostly the same with changing solution pH (Fig.6-6). The contour
mapping and 3D models indicate the screening result were accurate in that the zeta potential does
in fact decrease with an increase in solution pH. The RSM also confirmed that decreasing the
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chitosan concentration within these conditions increases the zeta potential. The bulk of the
curvature appears to be due to the chitosan-carrageenan mass ratio, which is also somewhat
shown in Figure 5-10.

Figure 6-4: Response surface 3D models and contour plots displaying the relationship between chitosan concentration and
chitosan to carrageenan mass ratio with mean particle diameter of chitosan-carrageenan nanoparticles for the pH values
of 4.5, 5.0 and 5.5. Medium MW chitosan, T=20±1°C.

Figure 6-5: A) Response surface 3D model and B) contour plot of the relationship between chitosan concentration and
chitosan to carrageenan mass ratio with the polydispersity of chitosan-carrageenan nanoparticles. Medium MW chitosan,
pH 5, T=20±1°C.
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Figure 6-6: Response surface 3D models and contour plots displaying the relationship between chitosan concentration and
chitosan to carrageenan mass ratio with the zeta potential of chitosan-carrageenan nanoparticles for the pH values 4.5,
5.0 and 5.5. Medium MW chitosan, T=20±1°C.
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Chapter 7
7 Encapsulation and Controlled Release of rHu-EPO
The encapsulation was performed, as described in Chapter 3 (Materials and Methods), by
the addition of 100µL of rHu-EPO into the chitosan solution during the nanoparticle production
process. The RSMs were used to determine the optimal conditions for nanoparticle formation
with small diameter, high surface charge and low polydispersity being the targets. The goal was
to strike a balance between these characteristics by producing the overall optimal particle;
however, somewhat more importance was placed on surface charge. The encapsulation and
controlled release of rHu-EPO from chitosan-TPP nanoparticles had previously been explored by
Bokharaei et al [92]; however, not in as much depth. The application of chitosan-carrageenan
nanoparticles as means of encapsulation and controlled release for rHu-EPO was a novel method
that had not been investigated.
Zeta potential was isolated as the most important factor, due to its significance to colloid
stability, and a study altering particle zeta potential was performed for both types of
nanoparticles with the hope that manipulating the zeta potential would allow for a method of
controlling the drug release rate. The effects of particle diameter and polydispersity could have
also been examined, but their influence on drug release, especially particle diameter, has a more
vital impact through the bodily nanoparticle clearance rate. This makes an investigation of the
effects of particle diameter and polydispersity better suited for an in vivo study, which is beyond
the scope of this research.
Chitosan MW has previously been reported to have affects on both the encapsulation and
drug release rate from chitosan microparticles. In a study by Genta et al., chitosan microspheres
generated through a modified dry-in-oil emulsion method demonstrated improved encapsulation
efficiency of ketoprofen when a mixture of high/low MW chitosan (2:1 w/w) was applied [94].
The drug release rate of ketoprofen and oxytetracycline from chitosan microspheres has been
reported to decrease with an increase in chitosan MW [94, 95]. When considering chitosan
nanoparticles the relationship between encapsulation efficiency and chitosan MW has not been
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as clear with reports that efficiency increases with increased chitosan MW and reports suggesting
the opposite relationship [96]. The relationship between chitosan MW and bovine serum albumin
release has previously been studied with results suggesting that increasing the chitosan MW
leads to a reduced protein release rate, which may be the result of reduced particle swelling with
increased chitosan MW and or the potential for the protein to bond at multiple sites [96].

7.2 Chitosan-TPP – Encapsulation and Controlled Release
When trying to balance different nanoparticle characteristics, but with a slightly higher
importance placed on surface charge, the RSMs yielded a chitosan concentration of 0.6mg/mL,
CS:TPP mass ratio of 4:1 and a pH level of 5.2 as the optimal conditions. According to the
model and confirmed by DLS and LDE, under these conditions a nanoparticle diameter of
~138nm, zeta potential of ~40mV and a polydispersity of ~0.275 can be achieved. The optimized
conditions yielded an encapsulation efficiency of 43.45±0.84% (Table 7-1), which is greater than
the 34.5% previously achieved using chitosan-TPP nanoparticles [92].
Table 7-1: rHu-EPO encapsulation results within chitosan-TPP.

Trial

Encapsulation
Mass Encapsulated (µg) Encapsulation Efficiency (%)
11.98±0.14
38.93±1.48
Low MW CS
i
13.37±0.08
43.45±0.84
Medium MW CS
14.07±0.06
45.71±0.63
High MW CS
12.21±0.12
39.70±0.63
~35mV - CS-TPP NPs
10.80±0.06
35.11±1.23
~30mV - CS-TPP NPs
i

The chitosan-TPP nanoparticles made with medium MW chitosan had a zeta potential of ~40mV.

A comparison of the effect of chitosan molecular weight on encapsulation and controlled
release of rHu-EPO was performed by using the above conditions with low and high MW
chitosan, in addition to the previously tested medium MW chitosan. As seen in Table 7-1, the
encapsulation efficiency increased when using high as compared to low MW chitosan possibly
due to an increase in the porosity of the nanoparticles, since the increase in the length of the
polymer chains should produce particles that are more porous. Another potential explanation is
that the structural formation of higher MW chitosan allows for more hydrogen bonding sites and
thus greater drug encapsulation [96]. The manipulation of the nanoparticle surface charge using
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the RSMs developed here and its effects on the encapsulation and controlled release of rHu-EPO
was another area of interest. The results showed that as surface charge increased so did the
encapsulation efficiency (Table 7-1).
The particle diameter and zeta potential of chitosan-TPP nanoparticles, produced under
the conditions suggested by optimization using the RSMs, were tested for both blank and rHuEPO loaded nanoparticles. The blank nanoparticle measurements showed a high degree of
agreement between the actual particle characteristics and those predicted by the RSMs, helping
prove their validity. The average difference between the particle diameter of blank and rHu-EPO
loaded nanoparticles was ~16nm and the average difference in zeta potential was ~8mV. The
addition of rHu-EPO was shown to increase the particle diameter, while decreasing the particle
zeta potential (Table 7-2). The decrease in the zeta potential appeared to be related to the
chitosan MW, with an increase in MW producing a larger decrease in zeta potential. This effect
could be connected to the encapsulation efficiency since increased chitosan MW led to increased
encapsulation of rHu-EPO, which would correspond to the greater drop in particle zeta potential
due to rHu-EPO’s negative charge. The results also implied that the lower the zeta potential
without the presence of rHu-EPO the larger the decrease in zeta potential when rHu-EPO is
encapsulated.
Table 7-2: Comparison of particle diameter and zeta potential between blank and EPO loaded chitosan-TPP
nanoparticles.

Particle Diameter (nm)
Trial

Zeta Potential (mV)

RSM
Prediction

Blank NPs

EPO- NPs

RSM
Prediction

Blank NPs

EPO- NPs

LMW CS

~

82.4±2.7

101.3±2.1

~

36.45±1.77

30.37±3.25

MMW CSi

138.2

140.3±2.5

155.6±1.7

39.7

39.18±1.61

31.82±3.20

HMW CS

~

148.4±2.3

169.5±1.8

~

38.31±1.86

29.86±1.09

138.6

136.5±1.9

148.1±2.9

35

35.95±2.24

27.59±1.56

143.7

140.2±2.4

153.1±2.1

30

29.15±1.97

19.58±1.80

~35mV
CS-TPP NPs
~30mV
CS-TPP NPs
i

The chitosan-TPP nanoparticles made with medium MW chitosan had a zeta potential of ~40mV.
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Figure 7-1: Comparison of rHu-EPO percent release over time for chitosan-TPP nanoparticles produced using low,
medium and high MW chitosan. [CS] = 0.6mg/mL, CS:TPP = 4:1, pH 5.2 and T= 20±1°C.

The optimized chitosan-TPP nanoparticles made with medium MW chitosan released
~30% percent of the encapsulated rHu-EPO in the first 24 hours, ~52% within the first week and
~68% within a two week period. These values are within the range of those previously reported
for biodegradable nano and microparticles, which ranged between 30-40% released within the
first 48 hours and between 60-80% released over a two week period [9,92].
When comparing the release of rHu-EPO from chitosan-TPP nanoparticles composed
with low, medium and high MW chitosan (Fig. 7-1) it can been seen that the rate of release
decreases with an increase in the chitosan MW. This is the opposite of the increase in
encapsulation efficiency with chitosan MW trend reported. The decrease in rate of release may
be due to a combination of reduced nanoparticle swelling with a higher chitosan MW and the
possibility of multiple bonding sites between rHu-EPO and chitosan [96]. The initial drug release
burst observed for most nanoparticles is due to the drug adsorbed to the particle surface and the
drug absorbed within the outer most layer of the particle matrix [2]. The surface charge study
72

(Fig. 7-2) demonstrated that as the zeta potential of the particles was increased from 30mV to
40mV the rate of release decreased. This data demonstrates clearly that altering the particle
surface charge, thus particle stability, can change the release characteristics. The nanoparticles
with surface charges of ~35mV and ~40mV were able to provide a steadier rate of release, where
as the ~30mV nanoparticles released the majority of the encapsulated drug within 3-4 days, after
which the release rate declined demonstrated by a decrease in separation between the percent
release of the ~30mV and ~35mV nanoparticles (More clearly displayed in Figure C-4,
Appendix C).

Figure 7-2: Comparison of rHu-EPO percent release over time for chitosan-TPP nanoparticles with surface charges of
~30mV, ~35mV and ~40mV. Medium MW chitosan, T= 20±1°C.
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7.3 Chitosan-Carrageenan – Encapsulation and Controlled Release
The optimized process conditions determined using the RSMs were a chitosan
concentration of 0.5mg/mL, a chitosan to carrageenan mass ratio of 3:1 and a pH of 5. RSM
predicted under these conditions a nanoparticle diameter of ~310nm, zeta potential of ~50mV
and a polydispersity of ~0.235 could be achieved and was confirmed by DLS and LDE (Table 74). Similar chitosan-TPP nanoparticles were investigated as an encapsulation and controlled
release mechanism for rHu-EPO and yielded an encapsulation efficiency of 34.5% [92], which is
considerably lower than the 47.97±4.10% obtained by this study’s chitosan-carrageenan
nanoparticles.
Table 7-3: rHu-EPO encapsulation results within chitosan-carrageenan.

Encapsulation
Mass Encapsulated (µg) Encapsulation Efficiency (%)
13.65±0.32
44.36±3.40
Low MW CS
i
14.76±0.58
47.97±4.10
Medium MW CS
15.58±0.20
50.13±2.11
High MW CS
13.77±0.05
44.74±0.51
~45mV - CS-CG NPs
13.01±0.21
42.28±2.17
~40mV - CS-CG NPs
Trial

i

These chitosan-carrageenan nanoparticles doubled as the ~50mV nanoparticles.

Under the RSM optimized conditions, the particle diameter and zeta potential of
chitosan-carrageenan nanoparticles were tested for both blank and rHu-EPO loaded
nanoparticles. The validity of the RSMs developed was furthered during this study since the
blank nanoparticle measurements demonstrated consistency between the actual particle
characteristics and those predicted by the RSMs. The average difference between the particle
diameter of blank and rHu-EPO loaded nanoparticles was ~19.5nm and the average difference in
zeta potential was ~7.5mV. Overall the addition of rHu-EPO was revealed to increase the
particle diameter and decrease the particle zeta potential (Table 7-4). Similar to the results for
chitosan-TPP nanoparticles, as the chitosan MW increased so did the drop in zeta potential when
rHu-EPO was added. Furthering the theory that the effect may be associated with encapsulation
efficiency since, again for chitosan-carrageenan nanoparticles, increasing chitosan MW led to
greater rHu-EPO encapsulation. Unlike the chitosan-TPP nanoparticles, the results did not imply
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that the lower the zeta potential without rHu-EPO incorporated the larger the drop in zeta
potential when rHu-EPO is encapsulated. The chitosan-carrageenan nanoparticles displayed a
trend of increasing difference in particle size between blank and rHu-EPO loaded nanoparticles
with increased chitosan MW and decreased initial particle zeta potential. These trends could be
explained using the same theories as before where the increase in rHu-EPO encapsulation, thus
the amount of rHu-EPO within the structure and on the particle surface, resulted in a greater
particle diameter and the decrease in initial particle zeta potential meant a more rapid
destabilization of the nanoparticles when rHu-EPO was included.
Table 7-4: Comparison of particle diameter and zeta potential between blank and EPO loaded chitosan-carrageenan
nanoparticles.

Particle Diameter (nm)
Trial

Zeta Potential (mV)

RSM
Prediction

Blank NPs

EPO- NPs

RSM
Prediction

Blank NPs

EPO- NPs

LMW CS

~

221.8±2.7

235.4±1.3

~

48.44±1.33

43.86±1.51

MMW CSi

311.0

305.9±2.8

322.2±4.3

50

48.89±0.94

42.22±2.38

HMW CS

~

307.1±3.3

334.7±3.7

~

47.37±0.62

37.43±0.96

309.1

316.1±2.4

334.2±3.6

45

44.74±0.73

35.60±2.84

316.2

318.8±3.1

340.0±4.1

40

40.82±0.67

33.75±1.43

~45mV
CS-CG NPs
~40mV
CS-CG NPs
i

These chitosan-carrageenan nanoparticles doubled as the ~50mV nanoparticles.

The effect of chitosan MW on the encapsulation and controlled release of rHu-EPO was
studied using three commercially available grades of chitosan (low, medium and high MW).
During this comparison all conditions were maintained at the optimum settings determined by
the RSMs and only the grade of chitosan was altered. It was found that as the MW of chitosan
was increased the encapsulation efficiency rose (Table 7-3), potentially due to an increase in the
nanoparticle porosity and changes in the sterical arrangement of the polymer chain, which may
allow for a greater number of hydrogen bonding sites between chitosan and the therapeutic agent
[96]. Another comparison was the effect of surface charge on encapsulation and controlled
release, which utilized the RSMs developed to manipulate the nanoparticle zeta potential. As the
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zeta potential increased from 40mV to 50mV the encapsulation efficiency of the chitosancarrageenan nanoparticles also increased.
The optimized chitosan-carrageenan nanoparticles (medium MW chitosan) in the first 48
hours released ~32% percent of the encapsulated rHu-EPO, in the first week ~42% and in a two
week time-span ~50%. When compared to other nano/microparticle rHu-EPO delivery systems
this rate of release is within the 30-40% range reported for the first 48 hours and is less than the
60-80% rate of release obtained during a period of two weeks [9, 92].

Figure 7-3: Comparison of rHu-EPO percent release over time for chitosan-carrageenan nanoparticles produced using
low, medium and high MW chitosan. [CS] = 0.5mg/mL, CS:CG = 3:1, 5.0 pH and T= 20±1°C.

For all of the trials conducted, the bulk of the drug release occurred within the initial 24
hours and is most likely due to a large amount of rHu-EPO adsorbed to the particle surface [5].
Altering the chitosan MW from low to high decreased the amount of rHu-EPO released, with the
main difference in release rate being within the first 12 hours (Fig. 7-3). The decrease in rHuEPO release rate, as mentioned earlier, may be due to an increase in the number of bonding sites,
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which could lead to multiple bonds between chitosan and rHu-EPO reducing the rate of release.
Also, mentioned previously, the nanoparticle swelling decreases with an increase in chitosan
MW, which could contribute to a decreased release rate. The manipulation of nanoparticle zeta
potential between 50mV and 40mV demonstrated that decreasing the surface charge leads to
increased rHu-EPO release, evidence that manipulation of the nanoparticle surface charge can
allow for control over the drug release rate (Fig. 7-4).

Figure 7-4: Comparison of rHu-EPO percent release over time for chitosan-carrageenan nanoparticles with surface
charges of ~40mV, ~45mV and ~50mV. Medium MW chitosan, T= 20±1°C.
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Chapter 8
8 Conclusions and Recommendations
8.1 Conclusions
Chitosan-TPP and chitosan-carrageenan nanoparticles were generated through ionotropic
gelation using flush mixing under a variety of conditions to evaluate the effects of chitosan
concentration, chitosan to anion mass ratio and solution pH on the nanoparticle characteristics.
The resulting chitosan-TPP nanoparticles had particle diameters ranging between 100 and
400nm, surface charges between 30 and 50mV, and particle size distributions ranging between
0.2 and 0.4. While, the chitosan-carrageenan nanoparticles displayed particle diameters between
200 and 1000nm, surfaces charges between 40 and 55mV, and particle size distributions between
0.2 and 0.35. Both types of chitosan nanoparticles grew in size with an increase in chitosan
concentration; however, raising the chitosan to anion mass ratio caused the chitosan-TPP
nanoparticles to increase in diameter, while causing the chitosan-carrageenan nanoparticles to
decrease in diameter. Direct trends were identified between the chitosan concentration and
chitosan to anion mass ratio to zeta potential for chitosan-TPP nanoparticles, while chitosancarrageenan nanoparticles were shown to have a peak zeta potential at a chitosan concentration
of 0.5mg/mL, but demonstrated no other trends. The other important factor studied in the
screening process, polydispersity, was determined to increase with an increase in chitosan to
anion mass ratios for both types of chitosan nanoparticles. Investigation into the particle
morphology revealed that both chitosan-TPP and chitosan-carrageenan nanoparticles had no
prominent shape, such as a spherical shape. The chitosan-carrageenan morphology did reveal
that a significant amount of these nanoparticles had a hexagonal structure that could indicate
semi-crystal structure and growth after ionic gelation induced nucleation. The study on the effect
of pH on chitosan nanoparticle formation found that the zeta potential decreased with increasing
pH for both types of nanoparticles, as well as determined that particle diameter and
polydispersity for chitosan-TPP nanoparticles could be minimized at a solution pH of 5.5. The
exploration into the effect of chitosan MW on nanoparticle formation established that the larger
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the MW the larger the particle diameter; however, nanoparticles produced using medium MW
chitosan yielded both higher zeta potential and polydispersity.
From this screening process a more narrow range of conditions were selected to be
further investigated using the response surface methodology in hopes of creating a more accurate
method of controlling the nanoparticle characteristics. Accurate quadratic RSMs were generated
for the chitosan-TPP nanoparticles and their three target characteristics that could be used to
minimize particle size to as little as 98nm and polydispersity to as low as 0.16, and maximize
zeta potential to ~45mV. RSMs were also successfully generated for the chitosan-carrageenan
nanoparticle characteristics of particle diameter, zeta potential and polydispersity by linear,
quadratic and 2FI RSMs, respectively. Through manipulation of the process conditions using
these RSMs the chitosan-carrageenan nanoparticle diameter and polydispersity could be
minimized to ~260nm and ~0.16, while producing particle zeta potential as high as ~52.5mV is
possible. Optimized nanoparticles were produced by balancing the different particle
characteristics’ targets, with slightly more emphasis applied to surface charge. The RSMs
yielded a chitosan concentration of 0.6mg/mL, chitosan to TPP mass ratio of 4:1 and a pH level
of 5.2 as the optimal conditions for chitosan-TPP nanoparticle production. While, the optimized
process conditions determined using the RSMs for chitosan-carrageenan nanoparticles were a
chitosan concentration of 0.5mg/mL, a chitosan to carrageenan mass ratio of 3:1 and a pH of 5.
The optimized chitosan-TPP nanoparticles resulted in an encapsulation efficiency of
43.45±0.84% and released ~30% of the encapsulated rHu-EPO in 24 hours and ~68% within a
two week period. While, the optimized chitosan-carrageenan nanoparticles yielded an
encapsulation efficiency of 47.97±4.10% and released ~32% of the encapsulated rHu-EPO in 48
hours and ~50% within a two week period. Both of the encapsulation results, for the two
different chitosan nanoparticles, are an improvement over the previously reported encapsulation
efficiency of 34.5% [91]. The RSMs were also used to determine the effect of surface charge on
rHu-EPO encapsulation and release rate, and demonstrated that increasing the surface charge
increases the encapsulation efficiency and produces a more stable drug release, which were
trends seen in both types of chitosan nanoparticles. The surface charge study also showed that
through manipulation of the zeta potential nanoparticles that release a therapeutic agent within a
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certain desired timeframe can potentially be produced. The effect of chitosan molecular weight
on encapsulation and controlled release was determined through experimentation using low,
medium and high MW commercial grade chitosan and established that increasing the MW
improved the encapsulation efficiency and decreased the rHu-EPO rate of release from both
chitosan nanoparticles. The results of this research demonstrate the potential for chitosan
nanoparticles as a drug delivery system for rHu-EPO and other therapeutic agents, and the
importance of manipulating process conditions to achieve optimum results.

8.2 Recommendations
When comparing the chitosan-TPP and chitosan-carrageenan nanoparticles the results of
this work have shown that chitosan-TPP nanoparticles can be produced that have half the particle
diameter of that of the smallest chitosan-carrageenan nanoparticles generated. The difference in
particle size can be attributed to the difference in polymer length between TPP and the longer
carrageenan polymer. The chitosan-carrageenan nanoparticles over all had a greater zeta
potential than that of the chitosan-TPP nanoparticles, which later manifested itself in the
encapsulation and controlled release of rHu-EPO where the chitosan-carrageenan nanoparticles
outperformed the chitosan-TPP nanoparticles in both the encapsulation and controlled release.
Based on the results the chitosan-carrageenan nanoparticles appear to be a better drug delivery
mechanism for the encapsulation and controlled release rHu-EPO than chitosan-TPP
nanoparticles. However, the application of rHu-EPO must be taken into account since more
importance on particle diameter may mean that chitosan-TPP nanoparticles are more suited for
certain applications.
One of the more novel applications of rHu-EPO and potential use for rHu-EPO loaded
chitosan nanoparticles pertains to the compound’s tissue protective properties and their ability to
help patients recover after acute myocardial infarction (MI) [12, 97]. When developing a drug
delivery system for the application of rHu-EPO in treatment of MI the nanoparticle system could
be inserted onto the tissue at the site of treatment rather than intravenous injection. For such an
application the importance of particle size would be diminished, since the size constraints
associated with particles in circulation would be removed. Chitosan-carrageenan particles would
be the more ideal of the two types of chitosan nanoparticles created in this study for application
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in MI treatment, due its increased encapsulation and prolonged release of rHu-EPO, as well as
the removal of size limitations. The use of high MW chitosan would also increase encapsulation
and provide a longer more sustained release.
The chitosan-carrageenan nanoparticles did demonstrate a marked improved in
encapsulation and controlled release of rHu-EPO; however, the initial drug burst was still
witnessed and is an obstacle to maintaining a consistent and prolonged release. In order to get a
more consistent release mechanism the use of a cross-linker may be investigated, but as
discussed in Chapter 3 this is less than ideal due to the potentially harmful production conditions.
Chitosan-TPP nanoparticles coated with alginate were reported to have a significantly reduced
burst effect when releasing BSA [98]; thus, adding an outer layer, whether alginate or another
polyanion, could provide the extra resistance needed to prevent the initial rHu-EPO burst.
Further studies into the effect of nanoparticle structure on the biological activity of rHu-EPO and
in vivo release studies need to be performed in order determine the true potential of chitosan
nanoparticles for rHu-EPO encapsulation and controlled release.
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Appendices
A.

Screening Process

Table A-1: Chitosan-TPP nanoparticle diameter characterization. Medium MW chitosan, pH 5 and T=20±1°C.

CS-TPP
Mass Ratio

Particle Diameter (nm)
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 0.5mg/mL
3:1

110.5000

106.7±0.9

103.2±1.3

106.8±1.3

4:1

128.8000

125.1±1.9

125.9±2.9

126.6±2.2

5:1

142.9000

138.1±2.1

139.7±3.5

140.2±3.0

6:1

165.5000

165.7±5.7

170.2±3.7

167.1±5.7

7:1

Unstable

Unstable

Unstable

Unstable

Chitosan Concentration = 1.0mg/mL
3:1

164.4±1.0

158.9±1.8

155.7±1.3

159.7±1.4

4:1

184.0±1.9

184.6±2.2

181.4±1.3

183.3±1.8

5:1

207.3±0.4

209.2±1.9

208.2±2.5

208.2±1.8

6:1

230.6±2.9

230.9±2.9

232.1±3.3

231.2±3.0

7:1

259.4±3.7

251.2±4.1

263.1±1.4

257.9±3.3

Chitosan Concentration = 1.5mg/mL
3:1

227.3±1.6

223.5±1.5

220.31.2

223.7±1.4

4:1

235.1±2.0

235.6±2.0

234.4±1.9

235.0±2.0

5:1

243.3±2.0

243.0±1.5

245.0±4.3

243.8±2.9

6:1

241.2±1.6

242.8±3.2

238.7±2.2

242.9±2.6

7:1

241.3±2.5

241.0±1.3

244.7±2.7

240.3±2.1
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Table A-1 Continued
CS-TPP
Mass Ratio

Particle Diameter (nm)
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 2.0mg/mL
3:1

289.8±4.9

284.7±2.2

292.3±4.8

288.9±4.2

4:1

301.4±4.5

299.3±3.7

301.5±2.2

297.7±3.6

5:1

313.1±2.1

313.9±4.2

312.7±3.4

313.2±3.3

6:1

313.7±4.6

313.9±3.5

312.2±4.2

313.3±4.1

7:1

306.8±3.5

307.6±4.6

304.2±3.5

306.2±3.9

Chitosan Concentration = 3.0mg/mL
3:1

348.4±3.0

355.6±2.7

353.8±3.0

352.6±2.9

4:1

383.7±3.8

382.3±3.1

374.4±5.9

380.1±4.4

5:1

392.7±5.7

396.7±3.3

391.3±3.5

393.6±4.3

6:1

Aggregate

Aggregate

Aggregate

Aggregate

7:1

Aggregate

Aggregate

Aggregate

Aggregate
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Table A-2: Chitosan-TPP nanoparticle zeta potential characterization. Medium MW chitosan, pH 5 and T=20±1°C.

CS-TPP
Mass Ratio

Zeta Potential (mV)
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 0.5mg/mL
3:1

37.37±1.13

37.46±0.96

37.08±0.62

37.30±0.93

4:1

43.22±1.37

42.67±0.88

42.55±1.98

42.81±1.48

5:1

45.43±0.53

45.33±0.83

45.01±0.95

45.26±0.79

6:1

47.87±1.2

46.73±0.68

46.69±1.29

47.10±1.09

7:1

Unstable

Unstable

Unstable

Unstable

Chitosan Concentration = 1.0mg/mL
3:1

35.59±1.22

36.78±1.25

36.08±1.50

36.15±1.33

4:1

40.97±1.32

41.24±1.12

40.71±0.60

40.97±1.05

5:1

43.13±0.70

44.51±1.65

42.89±1.16

43.51±1.23

6:1

45.14±1.52

44.76±1.40

45.61±0.92

45.17±1.31

7:1

47.94±2.19

47.94±1.19

46.83±1.38

47.57±1.57

Chitosan Concentration = 1.5mg/mL
3:1

34.83±0.62

35.17±0.93

35.59±0.62

35.19±0.74

4:1

39.52±0.88

41.79±0.74

40.52±0.91

40.61±0.85

5:1

44.81±0.68

42.68±1.13

43.37±0.85

43.62±0.91

6:1

42.37±0.92

42.82±0.99

43.83±1.75

43.01±1.28

7:1

43.39±0.96

43.73±0.95

43.61±0.64

43.58±0.86

92

Table A-2 Continued
CS-TPP
Mass Ratio

Zeta Potential (mV)
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 2.0mg/mL
3:1

34.54±0.58

34.77±1.06

33.09±1.15

34.13±0.96

4:1

39.12±1.89

39.54±1.39

40.05±1.02

39.57±1.48

5:1

41.84±0.94

41.48±1.18

41.51±1.05

41.61±1.06

6:1

43.44±0.92

42.93±0.80

43.49±0.73

43.29±0.82

7:1

44.23±1.96

44.72±1.52

45.16±1.63

44.70±1.71

Chitosan Concentration = 3.0mg/mL
3:1

33.23±0.50

33.97±0.62

33.07±0.36

33.42±0.55

4:1

38.63±0.92

37.81±0.49

37.92±1.15

38.12±0.90

5:1

39.05±0.70

39.31±0.79

40.50±0.76

39.47±0.75

6:1

Aggregate

Aggregate

Aggregate

Aggregate

7:1

Aggregate

Aggregate

Aggregate

Aggregate
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Table A-3: Chitosan-TPP nanoparticle polydispersity characterization. Medium MW chitosan, pH 5 and T=20±1°C.

CS-TPP
Mass Ratio

Polydispersity
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 0.5mg/mL
3:1

0.290± 5.0e-3

0.271±0.011

0.263±7.0e-3

0.275±8.0e-3

4:1

0.314± 9.0e-3

0.326± 0.010

0.324±8.0e-3

0.321±9.0e-3

5:1

0.334± 0.011

0.359±5.0e-3

0.351±0.016

0.348±0.012

6:1

0.379±0.014

0.378± 0.020

0.373±0.022

0.377±0.019

7:1

Unstable

Unstable

Unstable

Unstable

Chitosan Concentration = 1.0mg/mL
3:1

0.257±0.016

0.249±5.0e-3

0.264±5.0e-3

0.257±0.010

4:1

0.301±6.0e-3

0.314±4.0e-3

0.306±8.0e-3

0.307±6.0e-3

5:1

0.321±9.0e-3

0.337±6.0e-3

0.326±3.0e-3

0.328±6.0e-3

6:1

0.339±8.0e-3

0.354±8.0e-3

0.355±8.0e-3

0.349±8.0e-3

7:1

0.361±8.0e-3

0.358±9.0e-3

0.370±7.0e-3

0.363±8.0e-3

Chitosan Concentration = 1.5mg/mL
3:1

0.242±6.0e-3

0.243±0.014

0.218±0.013

0.234±0.012

4:1

0.281±7.0e-3

0.280±0.010

0.281±7.0e-3

0.281±8.0e-3

5:1

0.315±0.010

0.314±8.0e-3

0.293±0.014

0.307±0.011

6:1

0.314±8.0e-3

0.319±4.0e-3

0.315±6.0e-3

0.316±6.0e-3

7:1

0.284±5.0e-3

0.305±0.010

0.315±0.011

0.301±9.0e-3
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Table A-3 Continued
CS-TPP
Mass Ratio

Polydispersity
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 2.0mg/mL
3:1

0.257±0.010

0.261±0.012

0.269±0.015

0.262±0.013

4:1

0.297±0.018

0.298±6.0e-3

0.296±0.012

0.297±0.013

5:1

0.324±6.0e-3

0.321±0.019

0.315±0.013

0.320±0.014

6:1

0.327±0.012

0.324±0.016

0.323±9.0e-3

0.325±0.013

7:1

0.326±0.010

0.325±0.013

0.342±7.0e-3

0.331±0.010

Chitosan Concentration = 3.0mg/mL
3:1

0.287±0.014

0.272±0.013

0.277±0.012

0.279±0.013

4:1

0.318±7.0e-3

0.301±9.0e-3

0.300±0.016

0.306±0.011

5:1

0.319±6.0e-3

0.330±0.011

0.341±0.013

0.330±0.010

6:1

Aggregate

Aggregate

Aggregate

Aggregate

7:1

Aggregate

Aggregate

Aggregate

Aggregate
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Table A-4: Chitosan-TPP nanoparticle solution pH study data. Medium MW chitosan, [CS] = 1mg/mL, CS:TPP = 3:1, pH
5 and T=20±1°C.

Solution pH

Trial 1

Trial 2

Trial 3

Average

Particle Diameter (nm)
4.50

178.8±1.2

174.8±1.1

175.4±2.8

176.3±1.1

4.75

182.1±2.1

183.3±1.5

183.5±2.0

183.0±1.9

5.00

184.0±1.9

184.9±2.2

181.4±1.3

183.4±1.8

5.25

171.9±1.4

171.0± 1.7

172.4±1.5

171.8±1.5

5.50

165.2±1.4

165.6± 1.1

166.4± 0.7

165.7± 1.1

5.75

172.9± 1.7

176.6± 1.1

175.2±1.4

174.9±1.4

6.00

186.0±1.0

186.3±1.3

184.1±1.4

185.5±1.2

6.25

185.3±1.8

184.0±2.1

185.3±2.0

184.9±2.0

6.50

182.5±1.5

187.3±2.1

181.4±1.5

183.7±1.7

Polydispersity
4.50

0.311±6.0e-3

0.293±5.0e-3

0.302±5.0e-3

0.302±5.0e-3

4.75

0.286±8.0e-3

0.297±6.0e-3

0.293±7.0e-3

0.292±7.0e-3

5.00

0.301±6.0e-3

0.314±4.0e-3

0.306±8.0e-3

0.307±6.0e-3

5.25

0.243±8.0e-3

0.244±7.0e-3

0.244±7.0e-3

0.244±7.0e-3

5.50

0.201±0.011

0.195±0.012

0.213±6.0e-3

0.203±0.010

5.75

0.235±9.0e-3

0.231±7.0e-3

0.239±8.0e-3

0.235±8.0e-3

6.00

0.246±6.0e-3

0.270±9.0e-3

0.272±7.0e-3

0.263±7.0e-3

6.25

0.257±0.010

0.247±7.0e-3

0.253±9.0e-3

0.252±9.0e-3

6.50

0.265±9.0e-3

0.280±5.0e-3

0.251±0.010

0.265±8.0e-3
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TableA-4 Continued
Zeta Potential (mV)
4.50

44.79±1.15

44.68±1.45

44.98±1.54

44.82±1.39

4.75

41.69±1.80

42.43±1.35

41.46±1.68

41.86± 1.62

5.00

40.97±1.32

41.24± 1.12

40.71± 0.60

40.97± 1.06

5.25

36.95±1.29

37.94±1.69

37.75±1.66

37.55±1.56

5.50

35.19±0.92

34.59±1.16

35.94±0.64

35.24±0.93

5.75

32.29±1.41

31.57±1.20

32.53±1.38

32.13±1.33

6.00

30.79±1.49

29.73±1.39

29.65±1.47

30.06±1.45

6.25

25.05± 1.07

24.06± 1.71

25.31±1.57

24.81± 1.47

6.50

21.30±1.18

21.40±1.10

22.20±1.43

21.63±1.24

Figure A-1: Effect of chitosan concentration and chitosan to TPP mass ratio on the mean particle diameter of chitosanTPP nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5.
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Figure A-2: Effect of chitosan concentration and chitosan to TPP mass ratio on the zeta potential of chitosan-TPP
nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5.

Figure A-3: Effect of chitosan concentration and chitosan to TPP mass ratio on the polydispersity of chitosan-TPP
nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5.
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Table A-5: Chitosan-TPP nanoparticle MW study, particle diameter characterization. [CS] = 1mg/mL, pH 5 and
T=20±1°C.

CS-TPP
Mass Ratio

Particle Diameter (nm)
Trial 1

Trial 2

Trial 3

Average

Low MW Chitosan
3:1

92.1±0.8

89.5±0.4

87.6±0.6

90.2±0.4

4:1

93.6±1.4

90.9±0.7

92.7±1.3

92.4±1.2

5:1

99.8±2.7

93.3±0.6

98.5±2.3

97.2±2.1

6:1

99.2±1.4

103.9±2.2

106.8±1.8

103.3±1.8

7:1

113.2±2.6

116.0±2.6

117.7±4.4

115.6±3.3

Medium MW Chitosan
3:1

143.9±1.0

147.8±1.3

146.6±0.7

146.1±1.0

4:1

176.9±2.6

175.3±2.3

176.9±2.5

176.4±2.5

5:1

194.1±2.8

196.5±2.0

195.8±2.7

195.5±2.5

6:1

209.1±2.9

211.6±3.5

211.3±3.2

210.7±3.2

7:1

219.0±3.4

223.2±3.0

221.2±3.8

221.1±3.4

High MW Chitosan
3:1

183.0±2.5

182.0±1.9

183.5±1.6

182.8±2.0

4:1

191.2±2.2

189.5±2.4

187.4±1.9

189.4±2.2

5:1

188.1±3.0

189.5±2.3

188.0±2.6

188.5±2.6

6:1

182.3±2.0

183.3±2.3

182.2±1.7

182.6±2.0

7:1

180.7±2.2

182.5±3.2

181.2±3.2

181.5±2.9
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Table A-6: Chitosan-TPP nanoparticle MW study, zeta potential characterization. [CS] = 1mg/mL, pH 5 and T=20±1°C.

CS-TPP
Mass Ratio

Zeta Potential (mV)
Trial 1

Trial 2

Trial 3

Average

Low MW Chitosan
3:1

32.04±1.21

31.29±1.81

30.87±2.19

31.40±1.78

4:1

36.94±1.42

36.47±2.27

37.26±1.04

36.89±1.66

5:1

39.95±1.29

39.81±1.57

40.47±1.48

40.07±1.45

6:1

43.65±1.68

41.53±0.91

42.50±1.21

42.56±1.31

7:1

42.13±0.85

41.48±0.90

42.34±1.50

41.98±1.12

Medium MW Chitosan
3:1

32.02±1.08

32.87±0.60

33.20±0.95

32.70±0.89

4:1

39.10±1.11

40.35±0.85

40.48±1.06

39.98±1.01

5:1

42.47±0.86

42.09±0.80

42.88±0.92

42.48±0.86

6:1

42.81±1.01

44.02±1.79

44.17±1.46

43.67±1.56

7:1

44.97±1.14

44.10±1.48

45.29±1.17

44.79±1.27

High MW Chitosan
3:1

35.12±0.87

36.12±1.07

36.41±0.94

35.88±0.96

4:1

39.41±1.07

40.01±1.14

40.54±0.78

39.99±1.00

5:1

40.74±1.44

40.48±1.77

40.73±0.70

40.65±1.38

6:1

41.69±2.01

40.62±1.92

41.91±1.80

41.40±1.91

7:1

43.30±1.23

42.08±1.31

43.12±1.22

42.83±1.25
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Table A-7: Chitosan-TPP nanoparticle MW study, polydispersity characterization. [CS] = 1mg/mL, pH 5 and T=20±1°C.

CS-TPP
Mass Ratio

Polydispersity
Trial 1

Trial 2

Trial 3

Average

Low MW Chitosan
3:1

0.225±7.0e-3

0.188±0.013

0.199±0.013

0.204±0.011

4:1

0.241±8.0e-3

0.226±7.0e-3

0.252±6.0e-3

0.240±7.0e-3

5:1

0.277±8.0e-3

0.261±0.011

0.300±7.0e-3

0.279±9.0e-3

6:1

0.278±7.0e-3

0.292±5.0e-3

0.303±0.012

0.291±9.0e-3

7:1

0.332±6.0e-3

0.323±8.0e-3

0.322±7.0e-3

0.326±7.0e-3

Medium MW Chitosan
3:1

0.234±6.0e-3

0.230±9.0e-3

0.235±8.0e-3

0.233± 8.0e-3

4:1

0.311±4.0e-3

0.303±4.0e-3

0.300±4.0e-3

0.305±4.0e-3

5:1

0.324±4.0e-3

0.318±3.0e-3

0.327±5.0e-3

0.323±4.0e-3

6:1

0.355± 4.0e-3

0.345±7.0e-3

0.343±6.0e-3

0.348±6.0e-3

7:1

0.357±6.0e-3

0.344±9.0e-3

0.355±8.0e-3

0.352±8.0e-3

High MW Chitosan
3:1

0.251±8.0e-3

0.248±0.012

0.249±8.0e-3

0.249±5.0e-3

4:1

0.286±0.011

0.291±5.0e-3

0.283±0.011

0.287±9.0e-3

5:1

0.311±8.0e-3

0.323±9.0e-3

0.299±0.013

0.311±0.010

6:1

0.316±0.010

0.312±5.0e-3

0.314±4.0e-3

0.314±7.0e-3

7:1

0.317± 6.0e-3

0.326±6.0e-3

0.341±7.0e-3

0.328±6.0e-3
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Table A-8: Chitosan-carrageenan nanoparticle diameter characterization. Medium MW chitosan, pH 5 and T=20±1°C.

CS-CG
Mass Ratio

Particle Diameter (nm)
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 0.125mg/mL
2:1

208.6±3.9

202.3±1.7

198.2±3.0

203.0±3.0

3:1

181.9±3.7

184.2±2.1

180.2±5.4

182.1±4.0

4:1

405.4±33.1

394.2±28.7

368.6±24.6

389.4±29.0

5:1

Aggregate

Aggregate

Aggregate

Aggregate

6:1

Aggregate

Aggregate

Aggregate

Aggregate

Chitosan Concentration = 0.25mg/mL
2:1

253.0±2.4

248.5±2.1

247.9±1.9

249.8±2.1

3:1

232.8±3.1

234.1±4.2

230.0±1.7

232.3±3.2

4:1

210.9±2.6

216.8±2.9

210.4±2.5

212.7±2.7

5:1

213.4±4.7

211.0±2.2

215.0±2.4

213.1±3.3

6:1

224.6±2.4

227.8±3.1

226.2±3.7

226.2±3.1

Chitosan Concentration = 0.5mg/mL
2:1

340.1±4.4

339.0±4.5

333.1±3.8

337.4±4.2

3:1

278.8±1.6

288.1±1.6

275.9±1.8

280.9±1.7

4:1

266.7±1.8

265.4±2.3

259.6±1.4

263.9±1.9

5:1

253.9±1.7

251.6±2.6

244.4±3.7

250.0±2.8

6:1

241.8±3.7

252.3±2.3

255.6±2.0

250.0±2.8

7:1

244.5±3.2

250.5±3.2

252.9±3.0

249.3±3.1

102

Table A-8 Continued
CS-CG
Mass Ratio

Particle Diameter (nm)
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 1.0mg/mL
2:1

495.6±8.8

504.1±7.7

500.4±7.5

500.0±8.0

3:1

442.5±7.2

440.9±4.1

440.7±3.5

441.4±5.1

4:1

390.0±3.9

397.4±5.9

398.8±5.9

395.4±5.3

5:1

347.4±4.9

352.5±1.7

347.5±3.1

349.1±3.5

6:1

349.6±4.7

354.2±5.6

348.0±4.1

350.6±4.8

7:1

359.5±5.0

346.2±5.2

348.9±3.7

351.5±4.7

Chitosan Concentration = 2.0mg/mL
2:1

959.2±16.5

967.5±11.4

956.0±17.0

960.9±15.2

3:1

701.1±6.5

699.9±6.7

704.8±9.5

701.9±7.7

4:1

607.7±6.8

616.6±5.6

616.0±5.8

613.4±6.1

5:1

513.8±5.9

510.1±6.6

519.2±7.3

514.4±6.8

6:1

492.9±6.5

486.0±5.0

488.2±4.9

489.0±5.5

7:1

452.3±4.4

462.8±4.2

448.9±4.5

454.7±4.4
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Table A-9: Chitosan-carrageenan nanoparticle zeta potential characterization. Medium MW chitosan, pH 5 and
T=20±1°C.

CS-CG
Mass Ratio

Zeta Potential (mV)
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 0.125mg/mL
2:1

44.20±0.62

44.35±1.62

44.30±1.23

44.28±1.23

3:1

42.79±1.72

44.70±2.00

45.29±2.52

44.26±2.11

4:1

45.80±1.59

44.72±1.68

43.67±1.90

44.74±1.75

5:1

Aggregate

Aggregate

Aggregate

Aggregate

6:1

Aggregate

Aggregate

Aggregate

Aggregate

Chitosan Concentration = 0.25mg/mL
2:1

48.28±1.88

49.82±1.19

48.79±0.63

48.96±1.34

3:1

45.18±0.82

46.74±0.54

45.61±1.07

45.84±0.84

4:1

44.93±2.04

46.94±1.88

46.05±2.29

45.97±1.96

5:1

44.94±1.65

44.21±2.34

44.51±2.12

44.55±2.06

6:1

45.00±1.39

44.89±0.73

44.76±2.17

44.88±1.55

Chitosan Concentration = 0.5mg/mL
2:1

49.52±0.77

47.34±0.76

47.92±1.31

48.26±0.98

3:1

49.13±1.21

48.39±0.75

49.15±0.79

48.89±0.94

4:1

52.26±1.00

52.16±0.88

49.51±0.90

51.31±0.93

5:1

51.33±0.71

51.05±1.70

48.92±0.68

50.43±1.13

6:1

48.78±1.39

50.36±1.88

49.27±1.78

49.47±1.70

7:1

48.50±1.74

50.18±1.25

50.00±1.29

49.56±1.44
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Table A-9 Continued

CS-CG
Mass Ratio

Zeta Potential (mV)
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 1.0mg/mL
2:1

47.17±0.97

46.42±0.79

46.60±1.09

46.73±0.96

3:1

46.23±0.57

46.30±1.41

46.47±0.90

46.33±1.02

4:1

47.10±1.25

45.80±0.96

46.63±0.82

46.51±1.03

5:1

46.48±1.57

45.65±1.29

47.03±1.18

46.39±1.36

6:1

44.84±0.98

44.97±1.28

45.47±1.61

45.09±1.32

7:1

44.79±1.38

43.13±2.42

46.81±0.79

44.91±1.67

Chitosan Concentration = 2.0mg/mL
2:1

42.59±1.39

41.89±0.73

41.99±0.56

42.16±0.96

3:1

45.88±0.49

44.23±0.89

46.94±0.83

45.68±0.76

4:1

45.41±1.97

46.44±2.22

43.12±2.10

44.99±2.10

5:1

47.40±2.55

45.20±2.11

45.60±3.00

46.07±2.58

6:1

45.05±2.97

47.41±1.31

46.26±0.78

46.24±1.93

7:1

45.96±1.76

46.10±2.47

44.04±1.16

45.37±1.87
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Table A-10: Chitosan-carrageenan nanoparticle polydispersity characterization. Medium MW chitosan, pH 5 and
T=20±1°C.

CS-CG
Mass Ratio

Polydispersity
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 0.125mg/mL
2:1

0.280±5.0e-3

0.260±7.0e-3

0.266±7.0e-3

0.269±6.0e-3

3:1

0.323±0.010

0.332±0.013

0.336±0.020

0.329±0.015

4:1

0.376±0.053

0.400±0.012

0.368±0.017

0.381±0.033

5:1

Aggregate

Aggregate

Aggregate

Aggregate

6:1

Aggregate

Aggregate

Aggregate

Aggregate

Chitosan Concentration = 0.25mg/mL
2:1

0.251±0.011

0.217±0.021

0.268±5.0e-3

0.245±0.014

3:1

0.290±7.0e-3

0.313±7.0e-3

0.269±7.0e-3

0.291±6.0e-3

4:1

0.309±0.012

0.321±0.013

0.315±7.0e-3

0.315±0.011

5:1

0.320±9.0e-3

0.341±0.013

0.328±0.016

0.325±0.013

6:1

0.322±0.015

0.332±6.0e-3

0.339±9.0e-3

0.331±0.011

Chitosan Concentration = 0.5mg/mL
2:1

0.229±6.0e-3

0.247±5.0e-3

0.232±0.013

0.236±9.0e-3

3:1

0.245±0.010

0.246±0.021

0.242±0.012

0.244±0.015

4:1

0.269±9.0e-3

0.269±7.0e-3

0.282±9.0e-3

0.273±8.0e-3

5:1

0.288±0.015

0.286±8.0e-3

0.277±0.011

0.284±0.011

6:1

0.291±6.0e-3

0.305±0.015

0.291±8.0e-3

0.296±0.010

7:1

0.297±0.012

0.320±6.0e-3

0.309±8.0e-3

0.309±9.0e-3
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Table A-10 Continued
CS-CG
Mass Ratio

Polydispersity
Trial 1

Trial 2

Trial 3

Average

Chitosan Concentration = 1.0mg/mL
2:1

0.223±0.021

0.249±0.010

0.232±0.017

0.235±0.017

3:1

0.254±0.013

0.271±0.015

0.215±0.019

0.247±0.016

4:1

0.226±0.017

0.223± 0.026

0.223±0.028

0.224±0.024

5:1

0.255±0.013

0.247±0.022

0.235±0.024

0.246±0.020

6:1

0.266±0.013

0.276±0.027

0.275±0.024

0.272±0.022

7:1

0.272±0.010

0.279±0.018

0.264±0.022

0.272±0.017

Chitosan Concentration = 2.0mg/mL
2:1

0.282±0.019

0.277± 0.021

0.268±0.035

0.276±0.026

3:1

0.264±0.024

0.257±0.023

0.263±0.020

0.261±0.022

4:1

0.219±0.025

0.236±0.017

0.194±0.027

0.216±0.023

5:1

0.248±0.025

0.212±0.021

0.205±0.021

0.222±0.022

6:1

0.264±0.011

0.257±0.012

0.251±0.010

0.257±0.011

7:1

0.255±0.015

0.251±0.023

0.247±0.014

0.251±0.018
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Table A-11: Chitosan-carrageenan nanoparticle solution pH study data. Medium MW chitosan, [CS] = 0.5mg/mL,
CS:CG= 4:1, pH 5 and T=20±1°C.

Solution pH

Trial 1

Trial 2

Trial 3

Average

Particle Diameter (nm)
4.50

318.7±5.5

317.0±2.4

311.6±1.9

315.8±3.6

4.75

305.6±1.7

304.8±2.2

303.5±3.5

304.6±2.6

5.00

295.9±2.8

303.0±2.3

296.9±1.9

298.6±2.4

5.25

308.9±1.6

309.2±2.5

310.4±2.9

309.5±2.4

5.50

314.9±1.7

314.6±2.5

318.8±4.8

316.1±3.3

5.75

307.5±1.9

306.8±2.5

308.8±3.1

307.7±2.5

6.00

300.7±1.4

298.8±2.6

296.2±2.4

298.6±2.2

6.25

320. ±2.6

324.5±2.9

326.2±3.6

323.8±3.1

6.50

338.0±4.0

341.3±2.8

338.7±3.3

339.3±3.4

Polydispersity
4.50

0.235±0.025

0.233±0.018

0.247±0.012

0.238±0.019

4.75

0.234±0.021

0.235±0.020

0.239±0.018

0.236±0.020

5.00

0.264±0.011

0.239±0.021

0.220±0.014

0.241±0.016

5.25

0.239±0.018

0.245±0.021

0.228±0.015

0.237±0.018

5.50

0.244±0.017

0.225±0.011

0.224±0.023

0.231±0.018

5.75

0.235±0.017

0.228±0.013

0.226±0.015

0.230±0.015

6.00

0.190±0.019

0.240±0.014

0.228±0.015

0.219±0.016

6.25

0.226±0.021

0.218±0.019

0.229±0.016

0.224±0.019

6.50

0.215±0.035

0.223±0.018

0.228±9.0e-3

0.222± 0.023
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Table A-11 Continued
Zeta Potential (mV)
4.50

51.97±0.88

52.19±1.23

51.81±0.77

51.99±0.98

4.75

50.75±0.78

49.81±1.11

49.25±0.69

49.94±0.88

5.00

44.67±0.72

47.68±0.97

47.83±0.69

46.73±0.80

5.25

46.46±0.71

44.34±0.84

45.79±0.91

45.53±0.82

5.50

44.97±0.92

42.70±1.45

44.36±0.78

44.01±1.09

5.75

40.56±0.88

38.67±1.14

39.42±1.18

39.55±1.07

6.00

36.84±0.99

36.51±1.06

35.99±1.25

36.45±1.10

6.25

32.34±1.16

31.54±1.05

33.15±1.21

32.34±1.14

6.50

28.16±0.71

26.79±1.27

26.25±0.68

27.07±0.93

Figure A-4: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the mean particle diameter of
chitosan-carrageenan nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5.
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Figure A-5: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the zeta potential of chitosancarrageenan nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5.

Figure A-6: Effect of chitosan concentration and chitosan to carrageenan mass ratio on the polydispersity of chitosancarrageenan nanoparticles (Scatter plot). Medium MW chitosan, T= 20±1°C, pH 5.
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Table A-12: Chitosan-carrageenan nanoparticle MW study, particle diameter characterization. [CS] = 0.5mg/mL, pH 5
and T=20±1°C.

CS-CG
Mass Ratio

Particle Diameter (nm)
Trial 1

Trial 2

Average

Low MW Chitosan
2:1

248.3±4.1

254.9±3.2

251.6±3.7

3:1

223.6±3.0

225.9±1.7

224.8±2.4

4:1

204.6±2.9

204.3±3.6

204.5±3.3

5:1

192.1±2.4

190.5±2.0

191.3±2.2

6:1

191.8±2.1

188.8±3.1

190.3±2.6

Medium MW Chitosan
2:1

335.3±3.6

334.0±3.4

334.7±3.5

3:1

294.1±3.6.0

299.5±3.8

296.8±3.7

4:1

277.7±3.0

283.1±3.9

280.4±3.5

5:1

284.7±4.8

285.4±4.8

285.1±4.8

6:1

277.4±3.9

288.0±5.2

282.7±4.6

High MW Chitosan
2:1

339.1±1.4

355.4±2.0

347.3±1.7

3:1

298.0±3.5

296.1±2.6

297.1±3.1

4:1

268.6±2.6

272.8±3.0

270.7±2.8

5:1

263.9±3.6

259.6±2.2

261.8±3.0

6:1

247.4±4.2

251.9±4.6

249.7±4.4
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Table A-13: Chitosan-carrageenan nanoparticle MW study, zeta potential characterization. [CS] = 0.5mg/mL, pH 5 and
T=20±1°C.

CS-CG
Mass Ratio

Zeta Potential (mV)
Trial 1

Trial 2

Average

Low MW Chitosan
2:1

47.69±0.51

48.17±1.26

47.93±0.96

3:1

46.99±1.06

45.88±1.88

46.44±1.53

4:1

47.41±1.78

49.47±1.92

48.44±1.85

5:1

47.23±2.58

48.00±1.73

47.62±2.20

6:1

45.12±2.32

43.27±1.88

44.20±2.11

Medium MW Chitosan
2:1

50.58±1.39

48.51±0.88

49.55±1.16

3:1

48.35±0.58

47.21±1.08

47.78±0.87

4:1

50.04±1.98

51.04±0.98

50.54±1.56

5:1

49.70±0.28

50.02±1.16

49.86±0.84

6:1

44.17±3.31

47.35±3.29

45.76±3.30

High MW Chitosan
2:1

47.43±0.66

49.60±0.79

48.52±0.73

3:1

46.77±0.58

47.97±0.66

47.37±0.62

4:1

49.60±2.29

49.32±0.68

49.46±1.68

5:1

48.77±2.20

48.35±1.96

48.06±2.08

6:1

46.72±2.01

42.83±2.40

44.78±2.21

112

Table A-14: Chitosan-carrageenan nanoparticle MW study, polydispersity characterization. [CS] = 0.5mg/mL, pH 5 and
T=20±1°C.

CS-CG
Mass Ratio

Polydispersity
Trial 1

Trial 2

Average

Low MW Chitosan
2:1

0.190±0.014

0.158± 0.013

0.174±0.014

3:1

0.175±8.0e-3

0.193±0.011

0.184±0.010

4:1

0.230±7.0e-3

0.214±0.013

0.222±0.010

5:1

0.240±0.013

0.257±0.016

0.249±0.015

6:1

0.266±7.0e-3

0.282±0.012

0.274±0.010

Medium MW Chitosan
2:1

0.257±0.012

0.249±0.010

0.253±0.011

3:1

0.272±7.0e-3

0.274±8.0e-3

0.273±8.0e-3

4:1

0.303±7.0e-3

0.277±8.0e-3

0.290±8.0e-3

5:1

0.305±5.0e-3

0.307±8.0e-3

0.306±7.0e-3

6:1

0.308±6.0e-3

0.339±0.010

0.324±8.0e-3

High MW Chitosan
2:1

0.174±0.019

0.186±8.0e-3

0.180±0.015

3:1

0.211±0.016

0.236±0.012

0.224±0.014

4:1

0.246±6.0e-3

0.248±0.013

0.247±0.010

5:1

0.276±0.029

0.262±9.0e-3

0.269±0.022

6:1

0.273±9.0e-3

0.286±0.010

0.280±0.010
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B.

Chitosan Nanoparticle Response Surface Modeling

Table B-1: Chitosan-TPP nanoparticle RSM data.

Process Factors
CS Conc.
(mg/mL)
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
1
1
1
1
1
1
1
1
1
1
1
1
1
1

CS:TPP
Mass Ratio
3
3
3
3
3
3
4
4
4
5
5
5
5
5
5
3
3
3
4
4
4
4
4
4
4
4
4
5
5

Process Responses
Particle
Diameter
(nm)
103.2
110.5
106.7
108.4
110.3
103.5
137.1
135.5
139.8
138.1
142.9
139.7
167
174.5
178.2
156.6
158.4
159.9
184
184.6
181.4
166.4
165.2
165.6
186.3
184.1
186
174.4
165.3

Solution pH
5
5
5
6
6
6
5.5
5.5
5.5
5
5
5
6
6
6
5.5
5.5
5.5
5
5
5
5.5
5.5
5.5
6
6
6
5.5
5.5
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Zeta
Potential
(mV)
37.08
37.37
37.46
24.46
24.25
24.3
35.1
35.17
34.49
45.33
45.43
45.01
30.58
31.51
31.75
31.17
31.32
31.24
40.97
41.24
40.71
36.45
35.19
34.59
29.73
28.86
30.79
37.16
37.44

Polydispersity
0.263
0.29
0.271
0.259
0.258
0.246
0.245
0.257
0.247
0.359
0.334
0.371
0.35
0.365
0.342
0.166
0.166
0.177
0.301
0.314
0.306
0.213
0.201
0.195
0.27
0.272
0.246
0.239
0.236

Table B-1 Continue

1
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5

5
3
3
3
3
3
3
4
4
4
5
5
5
5
5
5

5.5
5
5
5
6
6
6
5.5
5.5
5.5
5
5
5
6
6
6

170.6
227.3
223.5
220.3
200.7
203.6
202.8
207.2
209.3
215
243
245
242.8
234.4
235
230.5
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37.9
34.83
35.17
35.59
30.74
30.47
28.95
38.74
37.77
38.07
38.8
39.42
40.73
35.88
35.41
35.21

0.232
0.242
0.243
0.218
0.275
0.272
0.269
0.252
0.254
0.258
0.314
0.293
0.314
0.307
0.327
0.324

Table B-2: Chitosan-carrageenan nanoparticle RSM data.

Process Factors
CS Conc.
(mg/mL)
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.75
0.75
0.75
0.75
0.75
0.75
0.75
0.75
0.75
0.75
0.75
0.75
0.75
0.75
0.75
1
1

CS:CG
Mass Ratio
3
3
3
3
3
3
5
5
5
5
5
5
4
4
4
3
3
3
4
4
4
5
5
5
4
4
4
4
4
4
3
3

Process Responses
Particle
Diameter
(nm)
318.7
317
311.6
314.9
314.6
318.8
274.5
273.3
276
268.3
264.5
263.1
266.7
265.4
259.6
357.6
360.6
353.8
328
328.8
330
301.9
305.9
294.7
346.4
335.4
346.3
328.5
328.1
325.4
404.7
401.6

Solution pH
4.5
4.5
4.5
5.5
5.5
5.5
4.5
4.5
4.5
5.5
5.5
5.5
5
5
5
5
5
5
5
5
5
5
5
5
4.5
4.5
4.5
5.5
5.5
5.5
4.5
4.5
116

Zeta
Potential
(mV)
51.97
51.19
51.81
44.97
41.89
44.36
48.02
48.92
50.06
41.59
41.86
41.53
52.26
52.16
49.51
48.96
50.12
49.64
44.72
45.77
44.52
44.69
44.65
44.35
48.36
50.71
50.57
41.57
44.71
41.52
48.67
48.25

Polydispersity
0.235
0.233
0.247
0.244
0.225
0.224
0.314
0.336
0.305
0.298
0.303
0.333
0.269
0.269
0.282
0.221
0.22
0.236
0.241
0.265
0.234
0.258
0.259
0.259
0.26
0.263
0.235
0.26
0.26
0.26
0.228
0.203

Table B-2 Continued
1
1
1
1
1
1
1
1
1
1
1
1
1

3
3
3
3
5
5
5
5
5
5
4
4
4

4.5
5.5
5.5
5.5
4.5
4.5
4.5
5.5
5.5
5.5
5
5
5

396.5
393.6
398
399.9
344.7
346.2
353.1
345.7
355
351.6
390
397.4
398.8
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47.31
40.6
37.51
37.58
49.28
45.89
47.47
41.03
41.33
39.5
47.1
45.8
46.63

0.248
0.234
0.213
0.205
0.272
0.275
0.262
0.256
0.255
0.213
0.226
0.223
0.223

C.

Encapsulation and Controlled Release of rHu-EPO

5e+5

Blank
1µg/mL rHu-EPO
2µg/mL rHu-EPO
3µg/mL rHu-EPO
4µg/mL rHu-EPO
6µg/mL rHu-EPO
8ug/mL rHu-EPO
12µg/mL rHu-EPO
24µg/mL rHu-EPO

Intensity

4e+5
3e+5
2e+5
1e+5
0
300

320

340

360

380

Wavelength (nm)
Figure C-1: Example of rHu-EPO fluorometer intensity readings used in creation of calibration curve.
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400

rHu-EPO Conc. (µg/mL)

30
25
20
15
10
5
0
0

1e+5

2e+5

3e+5

4e+5

5e+5

Peak Intensity
Figure C-2: Example of rHu-EPO calibration curve applied for conversion of intensity to concentration.

Table C-1: Chitosan MW study - rHu-EPO release from chitosan-TPP nanoparticles, cumulative mass release (µg/mL).

Cumulative Mass of rHu-EPO Released (µg/mL)
Time (h)
3
6
12
24
36
60
84
156
252
324

Low MW
2.07±0.01
3.67±0.51
4.69±1.10
~
5.79±1.19
6.66±0.47
7.19±0.93
7.83±0.53
9.14±0.01
10.46±0.05

Medium MW
1.86±0.01
3.01±0.05
3.77±0.17
4.06±0.41
5.01±0.34
5.71±0.23
6.02±0.15
6.96±0.21
7.75±0.26
9.03±0.27
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High MW
1.57±0.01
2.48±0.10
2.78±0.13
3.51±0.20
3.78±0.58
4.54±0.57
5.44±0.24
5.82±0.86
6.51±0.32
7.49±0.02

Table C-2: Chitosan MW study - rHu-EPO release from chitosan-TPP nanoparticles, percent release.

rHu-EPO Released (%)
Time (h)
3
6
12
24
36
60
84
156
252
324

Low MW
17.28±0.07
30.67±4.27
39.15±9.17
~
48.33±9.96
55.56±3.88
60.00±7.80
65.34±4.46
76.31±0.10
87.32±0.44

Medium MW
13.90±0.26
22.53±2.17
26.86±1.96
30.35±2.81
33.79±1.96
39.07±1.74
45.03±3.20
48.43±0.95
53.15± 0.82
60.26±0.83

High MW
11.20±0.07
17.63±0.73
19.75±0.91
24.93±1.42
26.86±4.13
32.26±4.02
38.65±1.66
41.37±6.10
46.29±2.29
53.23±0.15

Figure C-3: Comparison of the cumulative mass of rHu-EPO released over time for chitosan-TPP nanoparticles produced
using low, medium and high MW chitosan. [CS] = 0.6mg/mL, CS:TPP = 4:1, pH 5.2 and T= 20±1°C.
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Table C-3: Zeta Potential study - rHu-EPO release from chitosan-TPP nanoparticles, cumulative mass release (µg/mL).

Cumulative Mass of rHu-EPO Released (µg/mL)
Time (h)
3
6
12
24
36
60
84
156
252
324

~30mV NPs
2.58±0.01
4.21±0.01
4.92±0.01
~
6.79±0.01
7.32±0.01
7.75±0.01
8.40±0.01
9.04±0.01
9.36±0.01

~35mV NPs
2.32±0.02
3.67±0.01
4.44±0.02
~
5.96±0.04
6.58±0.12
7.12±0.13
8.06±0.07
9.01±0.02
9.52±0.09

~40mV NPs
1.86±0.01
3.01±0.05
3.77±0.17
4.06±0.41
5.01±0.34
5.71±0.23
6.02±0.15
6.96±0.21
7.75±0.26
9.03±0.27

Table C-4: Zeta Potential study - rHu-EPO release from chitosan-TPP nanoparticles, percent release.

rHu-EPO Released (%)
Time (h)
3
6
12
24
36
60
84
156
252
324

~30mV NPs
23.85±0.14
38.93±0.07
45.55±0.01
~
62.85±0.01
67.71±0.01
71.74±0.11
77.71±0.08
83.72±0.02
86.60±0.11

~35mV NPs
18.97± 0.13
30.08±0.01
36.37±0.20
~
48.77±0.29
53.90±0.97
58.29±1.07
65.98±0.54
73.76±0.16
77.96±0.72
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~40mV NPs
13.90±0.26
22.53±2.17
26.86±1.96
30.35±2.81
33.79±1.96
39.07±1.74
45.03±3.20
48.43±0.95
53.15±0.82
60.26±0.83

Figure C-4: Comparison of the cumulative mass of rHu-EPO released over time for chitosan-TPP nanoparticles with
surface charges of ~30mV, ~35mV and ~40mV. Medium MW chitosan (200cP – 400cP), T= 20±1°C.

Table C-5: Chitosan MW study - rHu-EPO release from chitosan-carrageenan nanoparticles, cumulative mass release
(µg/mL).

Cumulative Mass of rHu-EPO Released (µg/mL)
Time (h)
3
6
12
24
36
60
84
156
252
324

Low MW
2.01±0.08
2.75±0.09
3.57±0.04
~
4.80±0.38
5.50±0.18
6.13±0.18
6.67±0.14
7.66±0.19
8.56±0.08

Medium MW
1.58±0.13
2.16±0.09
2.71±0.02
3.55±0.14
4.33±0.06
5.02±0.10
5.45±0.08
6.10±0.18
6.73±0.29
7.37±0.24
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High MW
1.27±0.03
1.92±0.01
2.57±0.01
3.16±0.03
3.77±0.11
4.34±0.14
5.04±0.08
5.51±0.14
6.17±0.09
6.81±0.16

Table C-6: Chitosan MW study - rHu-EPO release from chitosan-carrageenan nanoparticles, percent release.

rHu-EPO Released (%)
Time (h)
3
6
12
24
36
60
84
156
252
324

Low MW
18.31±0.23
25.99±0.57
30.67±0.34
~
37.78±0.49
43.74±1.77
47.98±2.94
53.72±2.34
58.86±1.87
67.36±0.58

Medium MW
10.70±0.86
14.62±0.61
18.35±0.14
24.02±0.95
29.33±0.40
33.98±0.65
36.89±0.54
41.33±1.24
45.58±1.93
49.96±1.64

High MW
10.14±0.81
13.85±0.58
17.38±0.14
22.76±0.90
27.79±0.38
32.20±0.62
34.96±0.52
39.16±1.17
43.19±1.83
47.34±1.55

Figure C-5:Comparison of the cumulative mass of rHu-EPO released over time for chitosan-carrageenan nanoparticles
produced using low, medium and high MW chitosan. [CS] = 0.5mg/mL, CS:CG = 3:1, 5.0 pH and T= 20±1°C.
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Table C-7: Zeta Potential study - rHu-EPO release from chitosan-carrageenan nanoparticles, cumulative mass release
(µg/mL).

Cumulative Mass of rHu-EPO Released (µg/mL)
Time (h)
3
6
12
24
36
60
84
156
252
324

~40mV NPs
2.50±0.03
3.55±0.08
4.19±0.05
~
5.16±0.07
5.97±0.24
6.55±0.40
7.33±0.32
8.03±0.26
9.20±0.08

~45mV NPs
1.88±0.03
2.77±0.07
3.43±0.01
~
4.58±0.14
5.30±0.25
6.26±0.06
7.05±0.42
7.68±0.64
8.43±0.62

~50mV NPs
1.58±0.13
2.16±0.09
2.71±0.02
3.55±0.14
4.33±0.06
5.02±0.10
5.45±0.08
6.10±0.18
6.73±0.29
7.37±0.24

Table C-8: Zeta Potential study - rHu-EPO release from chitosan-carrageenan nanoparticles, percent release.

rHu-EPO Released (%)
Time (h)
3
6
12
24
36
60
84
156
252
324

~40mV NPs
19.22±0.24
27.27±0.59
32.18±0.36
~
39.64±0.52
45.90±1.85
50.35±3.09
56.37±2.46
61.76±1.96
70.68±0.61

~45mV NPs
13.64±0.19
20.11±0.53
24.90±0.06
~
33.24±1.01
38.53±1.81
45.48±0.44
51.21±3.05
55.78±4.62
61.26±4.49
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~50mV NPs
10.70±0.86
14.62±0.61
18.35±0.14
24.02±0.95
29.33±0.40
33.98±0.65
36.89±0.54
41.33±1.24
45.58±1.93
49.96±1.64

Figure C-6: Comparison of the cumulative mass of rHu-EPO released over time for chitosan-carrageenan nanoparticles
with surface charges of ~40mV, ~45mV and ~50mV. Medium MW chitosan (200cP – 400cP), T= 20±1°C.
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